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Abstract 
Dendritic cells (DCs) are the sentinels of the immune system, and thus specialized in transporting 
foreign antigen to T cells and initiating activation of innate and adaptive immune responses.  In 
this work, we first explore how DCs sense viral pathogens and stimulate antigen-specific T cell 
responses.  In particular, we find the DC-targeting HIV-1 derived lentiviral vector (LV) is a potent 
T cell vaccine in vivo. However, the exact mechanism behind such efficient immunization is not 
clear. Interestingly, we find that DC activation is triggered by cellular DNA packaged in LVs and at 
least partially dependent on the STING protein. Innate immune activation is independent of 
MyD88, TRIF and IPS-1, ruling out an involvement of Toll-like receptors or RIG-I-like receptor 
signaling. Further, we find that antigenic protein delivered in viral particles via pseudotransduction 
is sufficient to stimulate an antigen-specific immune response. Delivery of the viral genome 
encoding the antigen increases the magnitude of this response in vivo, but is irrelevant in vitro. 
Thus, pseudotransduction, genomic transduction, and STING-mediated activation thus 
collaborate to make the DC-targeted LV a uniquely powerful immunogen.  In addition, we explore 
how DCs mediate HIV-1 infection of T cells via cell-to-cell infection. In particular, we assess how 
DC-to-T cell transmission of HIV-1 allows for a concentrated amount of virus to be directed to an 
uninfected T cell. We report that DCs amplify the efficiency of T cell infection, resulting in anti-
retroviral drug insensitivity compared to T cell infection in the absence of DCs.  The DC-mediated 
amplification and drug-insensitivity of T cell infection are both entirely dependent on physical 
cellular interactions.  Further, we find that the input of a virus is important to the drug insensitivity 
of DC-to-T cell infection, but not DC-free T cell infection. Thus, we have studied two separate 
roles of DCs: initiating immune responses to LVs and mediating transmission of infectious HIV-1. 
The study of these roles is important to discovering novel immune adjuvants and identifying 
targeted therapeutics to inhibit viral dissemination.    
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Chapter 1 
 
Chapter 1: Introduction to the immune system, lentivectors, and transmission of HIV-1 
 
 
  
Overview of thesis  
In this thesis we explore the role of dendritic cells (DCs) in regulating the adaptive 
immune system and mediating the anti-viral immune response to HIV-1 derived lentiviral 
vectors (LVs).  The study of immunology and LVs is important in gaining understanding 
of anti-viral immunity as well as HIV-1 pathogenesis.  We seek to learn how DCs can be 
critical to the development of efficient anti-viral immune responses, but also be culprits in 
aiding viral dissemination.    
 
The first chapter will provide background information on LVs and HIV-1 and the innate 
immune response in mediating immunity and infection to these viral vectors.  It will also 
discuss the role of DCs in HIV-1 dissemination.  In chapter 2, we will explore in depth 
how LVs activate DCs and result in priming of antigen-specific memory T cells.  Our 
findings suggest that cellular DNA may act as a viral ligand to the STING pathway.  In 
chapter 3 we continue to explore the role of DCs in HIV-1 infection.  We find DCs that 
amplify HIV infection of T cells.  This mode of transmission is relatively resistant to 
reverse transcriptase inhibitors compared to T cell infection in the absence of DCs.  We 
consider the future directions and potential implications of this work in chapter 
5, and discuss ongoing work to investigate innate immune signaling pathways 
associated with LV and HIV recognition, viral heterogeneity, and ways to address cell-to-
cell infection. 
 
Overview of Dendritic Cells  
DCs are an important link between the innate and adaptive immune systems.  They are 
derived from cells in the bone marrow and reside in tissues throughout the body, 
sampling the environment and processing this information for activation of the adaptive 
immune system.  When DCs capture antigen and are activated, they will migrate to 
nearby lymphoid tissues.  The antigenic protein is presented on the surface of DCs on 
the major histocompatibility complex (MHC) to naïve T cells (Banchereau and Steinman, 
1998).  Activated DCs initiate the differentiation of naïve antigen-specific T cells into 
effector and memory T cells.  Non-activated DCs can also present antigen to T cells, but 
without stimulation signals T cell tolerance is generated (Heath and Carbone, 2001).  
Thus, activation of DCs is important in regulating immune stimulation versus tolerance. 
 
Overview of Innate Immune Recognition of Viral Pathogens 
DC maturation leads to the downregulation of antigen-capture activity, the increased 
expression of surface MHC class II molecules and co-stimulatory molecules, cytokine 
secretion, and migration to the draining lymph node (Trombetta and Mellman, 2005).  
DCs contain several families of surface and intracellular pathogen recognition receptors 
(PRRs), which detect a variety of conserved structures on pathogens, termed pathogen-
assoicated molecular patterns (PAMPs), and initiate appropriate intracellular cascading 
activation pathways. In certain instances, host factors can be recognized as “danger” 
signals, when they are presented in aberrant locations or abnormal molecular complexes 
as a consequence of infection, inflammation, or other types of cellular stress (Beg, 2002).  
PRRs that are thought to be important in sensing LVs and HIV-1 include Toll-like 
Receptors (TLRs), Rig-I-like Receptors (RLRs), and cytosolic nucleic acid sensors. 
 
The TLRs are the most extensively studied class of PRRs.  TLRs are composed of an 
extracellular or luminal ligand-binding domain containing leucine-rich repeat (LRR) 
motifs and a cytoplasmic signaling Toll/interleukin-1 (IL-1) receptor homology (TIR) 
domain (O'Neill and Bowie, 2007). Ligand binding to TLRs induces receptor 
oligomerization, which subsequently triggers intracellular signal cascades. To date, 10 
human TLRs and 13 mouse TLRs have been discovered (Mogensen, 2009). TLRs 3, 7, 
8, and 9 have been implicated in sensing viral pathogens.  TLR 3 recognizes dsRNA 
during viral replication (Alexopoulou et al., 2001); TLR 7 and 8 sense viral ssRNA 
(Diebold et al., 2004, Heil et al., 2004); and TLR9 senses unmethylated CpG DNA 
present in the virus genomes (Hemmi et al., 2000).  After ligand binding, TLRs recruit the 
TIR domain-containing adaptor molecules, which are critical to intracellular signal 
transduction.  MyD88 is a key adaptor molecule that is involved in signaling triggered by 
all TLRs, including TLRs 7, 8, and 9.  However, TLR 3 is dependent on signaling via the 
adaptor molecule TRIF.  Thus, the TLR pathways are often divided into MyD88-
dependent or MyD88-independent, TRIF-dependent.  Both pathways are capable of 
activating NF-KB, but may differ in their ability to induce proinflammatory cytokines and 
the anti-viral type I IFN response(Mogensen, 2009). 
 
Of the RLRs, RIG-I and melanoma differentiation-associated gene 5 (MDA5) are RNA 
helicases that sense cytoplasmic viral RNA and stimulate Type I IFN responses. The 
RLRs share highly conserved domain structures, including a central DExD/H-box 
helicase core composed of two helicase domains with a specific insertion within Hel-2 
and a C-terminal domain that confers part of the ligand specificity (Kolakofsky et al., 
2012). Although similar components are shared, the RIG-I and MDA5 have distinct viral 
sensing roles in certain cases.  For example, RIG-I has been shown to be essential in 
detecting paramyxoviruses and influenza virus, whereas MDA5 seems to be critical for 
the response to picornavirus and norovirus (Kato et al., 2006).  These differences may 
be due to length-dependent binding and recognition of 5’ triphophate ends on dsRNA 
(Kato et al., 2008).  However, both sensors are important in the sensing of Dengue Virus 
and West Nile Virus (Loo et al., 2008).  The intracellular signaling downstream of RIG-I 
and MDA5 depends on the adaptor protein IPS-1 (also known as MAVS, CARDIF, and 
VISA). The loss of IPS-1 abolishes the induction of type I IFN and proinflammatory 
cytokines in response to RNA viruses.    
 
Cytosolic sensors for DNA can signal through the adaptor protein, stimulator of IFN 
genes (STING), which is critical for inducing Type I IFN responses. Once activated by 
cytosolic DNA signaling, STING stimulates TBK1 and IRF3, resulting in type I IFN 
response. STING can also directly detect bacterial cyclic dinucleotides (Burdette et al., 
2011).  The definitive cytosolic DNA sensors that signals upstream to STING have not all 
been identified.  Currently, there are various putative cytosolic DNA sensors, which 
include Cyclic GMP-AMP synthase (cGAS), IFI16, DDX41, DNA-dependent protein 
kinases, catalytic subunit (DNA-PKcs), MRE11, and DNA-dependent activator of IRFs 
(DAI) (Fig. 1) (Wu and Chen, 2014).  It is to be determined whether cGAS functions only 
in specific cell types and whether other cytosolic DNA sensors signal in conjunction with 
cGAS. 
 
Overview of cytosolic DNA sensors of the Innate Immune System 
cGAS is activated by dsDNA through direct binding and catalyzes the production of 
cyclic GMP-AMP (cGAMP) from ATP and GTP. Structural analyses of cGAS show that 
the NTase and Mab21 domains and a unique zinc-binding motif are essential for B-form 
DNA binding (Civril et al., 2013).  Upon direct binding of DNA, conformational changes of 
the NTase domain occur, allowing better access of GTP and ATP substrates required for 
the catalytic reactions to generate the second messenger cGAMP(Civril et al., 2013, 
Xiao and Fitzgerald, 2013).  As a second messenger, cGAMP then activates the host 
STING signaling pathway.  Knockdown of cGAS in mammalian cell lines abolishes Type 
I IFN production induced by either DNA transfection or DNA virus infection (Gao et al., 
2013).  cGAS has also been shown to mediate the innate immune response to HIV and 
other retroviruses by detecting reverse-transcribed HIV-1 cDNA (Gao et al., 2013).    
 
IFI16 is a DNA-binding AIM2 related protein that interacts with DNA via its two HIN 
domains on the C-terminus.  It binds both dsDNA and ssDNA, which have both been 
shown to be stimulatory during lentiviral replication (Jakobsen et al., 2013).  In addition, 
IFI16 immunopreciptates with STING in dsDNA-stimulated THP-1 cells (Unterholzner et 
al., 2010).  Furthermore, knockdown of IFI16 leads to decreased antiviral Type I IFN 
response (Kis-Toth et al., 2011). However, there is no clear mechanism for how IFI16 
binds to STING.  IFI16 also has a PYRIN domain and PYRIN-containing proteins usually 
interact with one another.  STING does not have a PYRIN domain; thus, it is unclear if 
other proteins are involved in the IFI16-STING interaction or if the PYRIN domain is 
even involved in STING signaling.   
 
DDX41 was found in a systematic RNAi screen of a family of DExD/H helicases required 
for induction of type I IFNs by cytosolic DNA in mouse and human cell lines (Zhang et al., 
2012).  The knockdown of DDX41 led to decreased type I IFN production in response to 
cytosolic DNA, HSV-1 and bacterial cyclic nucleotides (Zhang et al., 2012, Parvatiyar et 
al., 2012).  In response to cytosolic DNA, DDX41 colocalizes with STING suggesting a 
connection with the STING signaling pathway (Parvatiyar et al., 2012).  DDX41 has a 
DEAD domain, which is responsible for binding to DNA, but a clearly defined signaling 
domain that is distinct from its nucleic acid–binding domain has not been identified. 
Therefore, it is unclear how DDX41 recruits signaling adaptors such as STING for 
downstream signaling. 
 
DNA-PKcs is an enzyme belonging to the phosphatidylinositol 3-kinase-related kinase 
(PI3K) protein family, which is required for the non-homologous end joining (NHEJ) 
pathway of DNA repair, which rejoins dsDNA breaks.  This complex was identified in 
affinity pull-down experiments as being directly bound to dsDNA and DNA-PKcs-
deficient mouse embryonic fibroblasts (MEFs) or mice showed decreased Type I IFN 
response to DNA virus infection (Ferguson et al., 2012).   
 
The protein MRE11A was also found to be involved in dsDNA repair and is involved in 
nonhomologous joining of DNA ends.  MRE11 has also been found to be a cytosolic 
dsDNA sensor, which signals through STING, but was not important to HSV-1 or L. 
monocytogenes anti-microbial responses (Kondo et al., 2013).  
 
DAI was the first putative cytosolic DNA sensor found to be important to DNA-mediated 
induction of type I IFN response in non-immune cell lines (Takaoka et al., 2007).  
However, later studies found that MEFs, dendritic cells, and macrophages deficient in 
DAI responded normally to DNA transfection or DNA virus infection.  Furthermore, DAI 
knockout mice showed normal immune responses to DNA vaccination (Ishii et al., 2008).   
 
Although great progress has been made in identifying putative cytosolic DNA sensors, 
the exact mechanism of cytosolic DNA innate immune sensing remains unclear.  It also 
remains to be seen how mechanisms involved in DNA damage repair overlap with viral 
DNA sensing pathways. 
 
Overview of DC vaccines including LVs 
Since DCs are critical to eliciting innate and adaptive immune responses, vaccination 
strategies involving DCs are being investigated. In particular, DC vaccines are currently 
being developed to stimulate tumor-specific effector and memory T cells that can clear 
and suppress tumor growth.  In order to achieve successful DC vaccination, tumor 
antigens have to be processed by the DCs and maturation of DCs has to occur.  For 
example, the ex vivo DC vaccine derives DCs from a patient, cultures them ex vivo, 
loads them with tumor antigens, matures them with an adjuvant, and then injects them 
back into the patient with the goal of eliciting tumor-specific effector T cells that induce 
tumor regression (Tacken et al., 2007).  However, this method is labor and resource-
intensive and only appropriate for a limited number of patients. In vivo targeting vaccines 
directly target DCs to take up antigen and become activated in vivo. This can be 
achieved by LVs, which are HIV-1-derived replication-defective vectors that effectively 
transduce dividing and non-dividing cells such as DCs. Thus, LVs are advantageous in 
their efficiency, manufacturability, and accessibility to a wide number of patients.  
 
To produce LVs, a reporter gene or gene of interest is cloned into a vector sequence 
between the LTRs.  This ensures that only the gene of interest becomes integrated into 
the target cell genome.  The viral genes required to generate the viral capsid, matrix, 
envelope, and enzymes are encoded on separate vectors (Fig. 2).  These vectors are on 
separate plasmids, to ensure the LV is replication-deficient.  After the plasmids are 
transfected into cells, LVs can be collected in the cell supernatant.  
 
The LV vaccine capitalizes on the ability of the vector to integrate and generate long-
term gene expression. Interestingly, the persistent expression of antigen does not lead 
to immunotolerance, but immunostimulation without evidence of exhaustion (Karwacz et 
al., 2009, Obst et al., 2007). This pattern of antigen persistence leading to effective 
memory responses instead of immune tolerance has also been seen with other viral 
infections (Zammit et al., 2006, Turner et al., 2007).  
 Since LV vaccines are being used clinically, it is critically important to understand how 
they stimulate innate and adaptive immunity.  The identification of the mechanisms that 
bestow LVs with their inherent ability to activate innate and adaptive will have great 
scientific and public health relevance, because it will deepen our understanding of host 
responses to viruses and ultimately develop effective vaccines against pathogens and 
cancer. 
 
Overview of cell-to-cell transmission of HIV-1 
DCs also play an important role in HIV-1 infection involving activation and coordination 
of innate and adaptive immune responses to the virus.  In addition, DCs may also play a 
role in the viral reservoir and dissemination via DC-mediated transmission of HIV-1 to 
CD4+ T cells.  DCs, in particular activated ones, are able to capture HIV-1 on their 
surface without being infected.  Virus particles concentrated at or near the surface of 
DCs are then transmitted to uninfected target CD4+ T cells via close contact in a 
process termed trans-infection (Fig. 3) (Turner et al., 2007, Coleman et al., 2013).  In 
contrast, HIV-1 can infect DCs, productively replicate and release viral particles to new 
target cells in a process called cis-infection.  However, productive infection of DCs is 
rare. 
 
Host cellular molecules have been demonstrated to affect DC-mediated transmission of 
HIV-1 to CD4+ T cells, including dendritic cell-specific intercellular adhesion molecule-3-
grabbing non-integrin (DC-SIGN), CD4, and intercellular adhesion molecules (ICAMs). 
Viral factors can also affect DC-mediated transmission of HIV-1 to CD4+ T cells, largely 
by directly interacting with and/or altering the expression of the host cell molecules. As 
such, the effects of viral factors on DC-mediated transmission of HIV-1 to CD4+ T cells 
will be described in the context of their effects on the host cell. 
 
There are host cellular molecules and viral factors that have been demonstrated to affect 
DC-mediated transmission of HIV-1 to CD4+ T cells. The DC-SIGN is a surface adhesion 
molecule highly expressed on DCs and is involved in formation of the virologic synapse 
and binds to HIV Env to capture the virus (Geijtenbeek et al., 2000).  The blocking of 
DC-SIGN inhibits and the overexpression ehances DC-mediated HIV transmission.  
However, DC-SIGN is mainly important for HIV transmission by immature DCs (Wang et 
al., 2007). Another surface adhesion molecule, ICAM-1, binds to Leukocyte function-
associated mocleule-1 (LFA-1) expressed on the surface of CD4+ T cells.  The 
interaction of these two molecules is important to stabilization of the virologic synapse, 
and thus for DC-to-T cell HIV transmission (Sanders et al., 2002).  The viral factors 
found to be important to DC-mediated viral tranmission include the composition of 
glycosolation of the HIV Env (van Montfort et al., 2011) and Nef protein (Sol-Foulon et al., 
2002).  
Further exploration is required to better understand the mechanism of how the virologic 
synapse forms and mediates HIV transmission between cells.   DC-mediated HIV-1 
transmission is likely a potent mode of infection, but the implication of how this relates to 
drug efficacy has yet to be explored.  This area needs to be further studied to develop 
strategies to inhibit persistent infection. 
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Table 1. List and description of human TLRs. 
  
  
Figure 1. Putative cytosolic DNA sensors.   
  
Figure 2. Schematic of plasmids required to generate lentivector (LV). 
  
  
Figure 3. Mechanisms of DC-mediated HIV-1 transmission to CD4+ T cells. 
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ABSTRACT 
Dendritic cell (DC)-targeted lentiviral vectors (LVs) deliver antigen and innate stimulation in vivo, 
resulting in strong T cell immunization. Here, we report that DC activation is triggered by cellular 
DNA packaged in LVs and is at least partially dependent on the STING protein. Activation is 
independent of MyD88, TRIF, and IPS-1, ruling out an involvement of Toll-like receptors or RIG-I-
like receptor signaling. Further, we find that antigenic protein delivered in viral particles via 
pseudotransduction is sufficient to stimulate an antigen-specific immune response. Delivery of the 
viral genome encoding the antigen increases the magnitude of this response in vivo, but is 
irrelevant in vitro. Pseudotransduction, genomic transduction, and STING-mediated activation 
thus collaborate to make the DC-targeted LV a uniquely powerful immunogen. 
  
INTRODUCTION 
Dendritic cells (DCs) are critical to stimulating adaptive immune responses owing to their 
superior ability to process antigens and present them to T cells.  Methods have been 
devised to directly target antigen to DCs for immunization purposes. One effective 
strategy uses an HIV-1-derived lentiviral vector (LV) to deliver genes encoding antigen to 
DCs as a T cell vaccine. LV can also target DCs by pseudotyping the vector with a 
mutant Sindbis virus glycoprotein (SVGmu), which binds to the DC-specific receptor DC-
SIGN.  The in vivo administration of this DC-targeted LV results in the selective 
expression of antigen in DCs and efficient priming of antigen-specific CD8+ T cells with 
potent anti-tumor immunity in mice that out-performs conventional methods using 
recombinant protein antigen or adoptive transfer of antigen-loaded or viral vector-
transduced DCs (Yang et al., 2008, Dai et al., 2009).  Recent work has shown that this 
form of DC immunization is also effective in humans (Somaiah, 2015, Odegard et al., 
2015). However, the exact mechanism behind such efficient immunization is not clear. It 
is evident that antigen delivery methods that lack a DC maturation signal — such as 
antigen conjugated to the DC-specific anti-DEC-205 antibody — lead to effective antigen 
presentation but promote tolerance rather than immunity (Bonifaz et al., 2002).  The co-
administration of anti-CD40 as a maturation stimulus is required to break immune 
tolerance. Thus, the success of DC-targeted LV immunization likely requires the 
coupling of two independent functions: delivery of antigen and activation of DCs.  
 
The first function — antigen delivery to DCs — is thought to primarily occur by LV 
transduction (Cowan et al., 2002). However, transduction of differentiated DCs in vitro is 
notoriously difficult due to the host restriction factor SAMHD-1, which blocks reverse 
transcription (Manel et al., 2010). The transduction of early stage or precursor DCs is 
more easily achieved, but these cells are not typically stimulated by the infection process 
(Dyall et al., 2001, He et al., 2005, Chinnasamy et al., 2000, Schroers et al., 2000, 
Breckpot et al., 2007, Rouas et al., 2002, Breckpot et al., 2003, Arce et al., 2009). Thus, 
it is not clear how LVs can concurrently deliver antigen and stimulate target DCs.  One 
possibility is that another mechanism of protein antigen delivery exists besides 
transduction.  For example, pseudotransduction is a process by which antigen 
expressed by the producer cells is carried by the vector into target cells (Haas et al., 
2000, Nash and Lever, 2004, Breckpot et al., 2007).  It is unknown if LV 
pseudotransduction plays a significant role in either antigen delivery and immune 
stimulation. 
 
The second function — stimulation of DCs — is expected to occur through the triggering 
of host intracellular innate immune sensing pathways. Differentiated DCs are well 
activated by the LV transduction process (Yang et al., 2008, Dyall et al., 2001, Breckpot 
et al., 2010, Metharom et al., 2001, He et al., 2005).  LV nucleic acids trigger endosomal 
Toll-like receptors (TLRs), which signal through the adaptor molecules MyD88 and/or 
TRIF (Breckpot et al., 2007, Beignon et al., 2005, Pichlmair et al., 2007, Breckpot et al., 
2010).  RNA helicase Rig-I-like receptors (RLRs), which signal through IPS-1 (also 
known as Cardif, MAVS, and VISA), detect cytosolic HIV genomic RNA (Berg et al., 
2012).  Finally, various cytosolic DNA sensors signal through the adaptor molecule 
STING (also known as TMEM173, MYPS, MITA and ERIS), and are involved in the 
detection of reverse transcribed lentiviral DNA (Jakobsen et al., 2013, Gao et al., 2013).  
However, it is not clear which of the LV components and intracellular innate immune 
detection pathways is critical to DC activation and subsequent development of adaptive 
immunity.  
 
Here we report LV pseudotransduction, a process by which antigen expressed by the 
producer cells is carried by the vector into target cells, contributes to antigen delivery, 
and is the primary mechanism of immune stimulation. LV transduction contributes to 
antigen delivery in vivo, but is not required for immune stimulation. In addition, LVs 
induced DC activation via the host STING pathway, independent of TLR and RLR 
signaling. We found encapsulated human genomic DNA is a previously unidentified 
constituent of virion preparations that can be recognized by the cytosolic DNA-sensing 
STING pathway. 
 
RESULTS 
LVs pseudotransduce DCs via protein delivery  
We first sought to understand the mechanism of antigen delivery to differentiated DCs by 
LVs.  We differentiated DCs by culturing mouse bone marrow cells and human 
monocytes in media containing the appropriate cytokines for eight days.  We then 
treated these differentiated DCs with vesicular stomatitis virus glycoprotein (VSV-G)-
pseudotyped LV expressing green fluorescent protein (GFP) at a multiplicity of infection 
(MOI) of one.  The LV-treated DCs expressed a low but significant level of GFP by flow 
cytometry (Figures S1A and S1C), which was undiminished by reverse transcriptase 
inhibitors (RTIs) (Figures 1A and 1B).  By contrast, 293T cells treated with the same 
dose of LVs were efficiently transduced, as evidenced by a higher level of GFP 
expression, which was sensitive to RTIs (Figures 1A and 1B).  The expression of GFP 
in DCs was highest immediately after LV treatment and then steadily decreased over 48 
h (Figure S1C).  In addition, we found that the protein synthesis inhibitor cycloheximide 
failed to decrease GFP expression, indicating that the GFP detected immediately after 
LV treatment was not produced de novo (Figure 1C).  We also detected the protein GFP 
in LV lysate by Western blot analysis (Figure 1D), which indicated the presence of 
approximately one microgram of GFP per microgram of p24 by enzyme-linked 
immunosorbent assay (ELISA) (data not shown).  This ability of LVs to incorporate 
vector-encoded protein was not specific to GFP because we also detected ovalbumin 
(OVA) in the lysate of LV encoding OVA (Figure S2A).  These results are consistent 
with previous reports, indicating that LVs carry protein (Haas et al., 2000, Nash and 
Lever, 2004, Breckpot et al., 2007) and poorly transduce differentiated DCs in vitro 
(Schroers et al., 2000, Metharom et al., 2001, He et al., 2005, Manel et al., 2010).   
Retroviral particles have been found to carry cellular mRNA (Galla et al., 2004) and 
bacterial plasmids (Pichlmair et al., 2007), which could contribute to GFP expression in 
the target cell.  However, since the GFP expression was insensitive to cycloheximide 
(Figure 1C), this suggests that GFP was not generated de novo in the DC, but likely 
delivered via pseudotransduction.  
 
LV pseudotransduction of DCs induces activation 
We next sought to determine whether LV pseudotransduction resulted in activation of 
differentiated DCs.  We observed LV pseudotransduced mouse bone marrow derived 
DCs (BMDCs) were activated similarly to LPS treatment (Figure S1B).  This activation 
was not diminished by RTIs, as demonstrated by the undiminished expression of DC 
activation markers CD86 and mouse MHCII molecule I-Ab (Figure 1E). LV 
pseudotransduced human monocyte-derived DCs (moDCs) were also activated and 
unaffected by RTIs (Figure 1F).  This lack of sensitivity to RTIs was not due to 
ineffective inhibition of reverse transcription because the RTIs significantly blocked GFP 
transduction in LV-infected 293T cells (Figure 1A and 1B). These results suggest that 
LV pseudotransduced DCs are activated by a reverse transcriptase-independent 
mechanism.  
 
Viral envelope is an important immunostimulatory component 
Next, we sought to systematically determine the LV component responsible for DC 
activation. We generated a platform of genome-less VLPs by exploiting the modularity of 
the LV system and omitted plasmids encoding the viral genome, capsid or envelope 
(Figure 2A) (Pichlmair et al., 2007, Mangeot et al., 2011).  We confirmed the presence 
or absence of the viral envelope and capsid in these VLPs by Western blot analysis for 
VSV-G and p24 (Figure 2B).  Similar to LVs, we found that pseudotyped VLPs 
incorporated vector-encoded proteins such as GFP or OVA (Figures 2B and S2B).  
However, “bald” viral particles, which were produced by transfecting 293T producer cells 
with the LV packaging plasmids encoding gag, pol, and rev (Cowan et al., 2002), were 
not capable of incorporating vector-encoded proteins. We next assessed whether these 
proteins were carried within the VLP or associated externally.   We pre-treated VLP 
incorporating OVA with proteinase K, and then inactivated the proteinase K with 
phenylmethylsulfonyl fluoride (PMSF) before lysis of the particles, and still detected OVA 
in the VLP lysate, indicating that OVA was carried within the VLP (Figure S2C). If the 
proteinase K was not inactivated prior to particle lysis, OVA was no longer detected.  We 
next determined whether VLPs were capable of delivering vector-encoded proteins to 
DCs.  We observed the VSV-G or SVGmu envelope was required for VLPs to deliver 
GFP into mouse BMDCs and human moDCs (Figure 2C).  In addition, pseudotyped 
VLPs, but not “bald” VLPs, induced activation of DCs (Figure 2D).  The inclusion of the 
vector genome or viral capsid had no effect on DC activation.  Also, VLPs lacking the 
viral genome and capsid efficiently activated human moDCs (Figure 2E).  Altogether 
these data suggest that the viral envelope, but not the vector genome or capsid, was 
necessary and sufficient to activate DCs. 
 
LV genome, cDNA, and capsid are not required for immune stimulation in vivo  
To determine whether these findings were relevant in vivo, we examined whether 
reverse transcription and the LV genome were required for LV immunization. Prior work 
demonstrated that LV expressing OVA and pseudotyped with SVGmu (LV-OVA) was 
DC-specific and elicited potent OVA-specific CD8+ T cell responses (Yang et al., 2008). 
We injected the DC-targeted LV-OVA into mice with or without a concurrent oral regimen 
of RTIs. The administration of these RTIs was initiated one week prior to LV-OVA 
immunization and continued throughout the experiment. To determine the importance of 
the viral genome, we immunized mice with VLP carrying OVA pseudotyped with SVGmu 
(VLP-OVA).  Both the LV-OVA and VLP-OVA used in this experiment carried OVA 
protein, the viral capsid, and the SVGmu envelope, but only the LV carried the viral 
genome. We pseudotyped all vectors used for immunization with the SVGmu envelope 
to limit off-target cell effects. We initially found OVA-specific effector memory CD8+ T 
cells were similarly induced in mice treated with LV-OVA with or without RTIs or VLP-
OVA at seven days post-immunization (Figure 2F top row).  However, through ten days 
post-immunization, the magnitude of the OVA-specific CD8+ T cells continued to 
increase in LV-immunized mice, but not in the LV-OVA with RTIs or VLP-immunized 
mice (Figure 2F bottom row).  After a second administration of homologous vector, the 
secondary OVA-specific CD8+ T cell responses demonstrated more rapid kinetics and 
higher magnitudes than the primary immune response in all three groups (Figure 2G).  
In addition, these OVA-specific CD8+ T cells expressed similar effector memory 
phenotypes (CD62LloCD44hi) in all three groups (Figure 2H). The primary and 
secondary immunization responses were similar between the mice receiving LV with 
RTIs and VLP, suggesting that a component of LV immunization is independent of 
reverse transcription and the viral genome, thus, likely due to pseudotransduction. 
 
After the secondary immune responses subsided, we next assessed the in vivo function 
of the prime-boosted CD8+ T cell responses using an OVA-expressing tumor model.  We 
injected OVA-expressing tumor cells and control non-OVA-expressing tumor cells on 
opposing legs, enabling intra-animal comparison. Mice homologously primed and 
boosted with LV with or without RTIs or VLPs were effectively protected against the 
growth of OVA-expressing tumors (Figure 2I). The non-OVA-expressing tumor cells 
continued to grow in the mice as expected.  The efficient anti-tumor protection of LV with 
RTI and VLP-immunized mice is not altogether surprising since 8-10% of the CD8+ T 
cells were OVA-specific after the boost.  Therefore, the vector genome and its 
transduction enhanced, but were not necessary to inducing memory CD8+ T cells.  
These results suggest that LV pseudotransduction is sufficient to induce a functional 
memory CD8+ T cell response. 
 
To investigate the immunostimulatory effect of the viral capsid and envelope we 
homologously prime-boosted mice with VLPs carrying OVA with or without the viral 
capsid (VLP-OVA or VLP-OVAΔgag, respectively).  Both immunization groups 
developed similar primary and secondary CD8+ T cell responses and were effectively 
protected against the growth of OVA-expressing tumors (Figures 2J and 2K).  Therefore, 
VLPs, which have the viral envelope as the sole viral component, generated a 
sufficiently strong memory CD8+ T cell response protective against the growth of OVA-
expressing tumor cells.  The viral capsid did not enhance immunization responses.  
Thus, the viral envelope of the vector is sufficient in stimulating LV immunization 
responses in vivo. 
 
LV transduction enhances antigen delivery 
We next aimed to understand why LV immunization generated a higher magnitude of 
memory CD8+ T cells compared to LV with RTI or VLP immunizations. We hypothesized 
that LV transduction contributes to antigen delivery rather than immune stimulation. We 
generated an SVGmu-pseudotyped LV encoding GFP and carrying the protein OVA (LV-
GFPgene-OVAprotein) by transiently transfection of 293T cells with the plasmids required to 
produce GFP-expressing LV and an expression plasmid for OVA.  Because the vector in 
these virions did not encode OVA, the OVA-specific CD8+ T cells induced would be a 
result of LV pseudotransduction.  Additionally, because this vector was capable of 
reverse transcription, it would indicate if reverse transcribed LV DNA was an immune 
adjuvant. This vector induced an OVA-specific CD8+ T cell response similar to VLP-
immunized mice (Figure 2L), suggesting that reverse transcribed LV DNA itself is not an 
immune adjuvant to the antigen-specific CD8+ T cell response produced by 
pseudovirions.  There should not be antigenic competition between GFP and OVA 
because GFP is minimally antigenic and fails to elicit a GFP-specific CD8+ T response in 
C57/B6 mice (Skelton et al., 2001). Thus, this data suggests antigen delivery during LV 
immunization is an additive process between pseudotransduction and transduction.  
However, LV genome transduction does not appear to contribute to immune stimulation.   
 
LVs activate DCs and adaptive immunity via STING pathway 
We next set out to identify the innate immune signaling pathway responsible for LV 
detection, DC maturation, and subsequent priming of CD8+ T cells. We treated BMDCs 
from mice deficient in MyD88, TRIF, or IPS-1 with an LV expressing GFP pseudotyped 
with VSV-G or SVGmu.  Consistent with prior work, we found that the two vectors, VSV-
G and SVGmu-pseudotyped LVs, similarly activated wild-type BMDCs (Figure S1).  We 
observed that LVs capably activated BMDCs from mice deficient in MyD88, TRIF, or 
IPS-1 (Figure 3A).  To examine the possibility of redundant pathways, we treated 
BMDCs from mice doubly deficient in MyD88 and TRIF or MyD88 and IPS-1 with LV and 
found that DC activation was still unaffected (Figures S3A and S3B). To study activation 
of DCs in vivo we injected the DC-targeted LV-OVA into mice deficient in MyD88, TRIF, 
or IPS-1 and measured OVA-specific CD8+ T cells. We found that OVA-specific effector 
memory CD8+ T cells fully developed in mice deficient in MyD88, TRIF, or IPS-1 at 
similar levels to wild-type mice (Figures 3B-3E). These findings suggest that LV innate 
immune detection and subsequent adaptive immunity do not depend on TLR and RLR 
signaling pathways. 
 
We turned to the STING-signaling pathway, an important adaptor protein involved in 
cytosolic viral DNA sensing.  To address whether STING was important in LV detection, 
we injected STING-deficient mice with the DC-targeted LV-OVA and found a significantly 
diminished OVA-specific CD8+ T cell response compared to wild-type mice immunized 
with LV-OVA (Figures 3E and 3F).  Consistent with other work, we noted normal T cell 
subsets in unimmunized STING-deficient mice (Figure S4) (Ishikawa et al., 2009).  
These results indicate that LV activation of DCs and CD8+ T cell response is partially 
dependent on STING. 
 
VLPs activate DCs and adaptive immunity via STING pathway 
We next investigated whether the reverse transcribed LV DNA was required to induce 
the STING-dependent immune response. We infected mouse BMDCs from STING-
deficient mice with VSV-G or SVGmu-pseudotyped VLP carrying GFP and found that 
maturation was partially dependent on STING (Figure 4A), suggesting a component 
other than the viral genome could activate STING.  In addition, STING-deficient BMDCs 
treated with VLP carrying OVA had a reduced ability to activate OT-1 CD8+ T cells, 
which express an OVA-specific TCR, as demonstrated by the reduced expression of T 
cell activation surface markers, CD69 and CD25 (Figure 4B).  We next treated STING-
deficient mice with a homologous prime-boost vaccination of the DC-targeted VLP-OVA, 
which lacked the LV genome and capsid, and observed significantly less effector 
memory CD8+ T cells in the STING-deficient mice (Figures 4C-4E). Altogether, these 
results demonstrate that a component other than the lentiviral genome or reverse 
transcribed LV DNA can trigger the host STING pathway.  
 
Viral fusion is required for DC activation  
Since we found that the viral envelope was necessary and sufficient for stimulating DCs, 
we next focused on understanding this mechanism of activation. The viral envelopes of 
vesicular stomatitis virus and Sindbis virus induce cell-surface receptor mediated 
endocytosis and release viral contents into the cytosol through pH-dependent viral fusion 
between the viral envelope and host endosomal membrane (Florkiewicz and Rose, 1984, 
Smit et al., 1999).  To investigate the importance of viral fusion on DC activation, we 
treated mouse BMDCs with pseudotyped VLPs devoid of the LV genome and capsid or 
LVs in the presence of the fusion inhibitor chloroquine (Dille and Johnson, 1982).  We 
observed that DC activation by VLPs and LVs was abolished in the presence of 
chloroquine (Figure 5A).  This effect was not due to lack of internalization because 
intracellular punctate GFP was evident in the chloroquine-treated cells  (Figure 5B).  We 
next used an altered VSV-G, in which mutations rendered the protein fusion-defective 
without altering envelope binding or receptor-mediated endocytosis (Zhang and Ghosh, 
1994). BMDCs treated with fusion-competent VLP displayed diffuse intracellular GFP 
presence by microscopy, whereas DCs treated with the fusion-defective VLP showed 
punctate GFP presence similar to chloroquine-treated cells (Figure 5B). We also 
observed the fusion-defective LV and VLP failed to activate mouse BMDCs (Figure 5C). 
Thus, these findings suggest that viral fusion is required for LV and VLP activation of 
DCs.  
 
We next asked whether the viral process of membrane fusion itself and/or the release of 
a putative activating component into the cytosol represented the activating stimuli.  To 
first determine whether VSV-G-mediated fusion itself was immunostimulatory we 
incorporated VSV-G into the lipid membrane of non-cationic multilamellar liposomes, 
which allows for the liposomal contents to evade lysosomal degradation and be 
delivered into the cytosol via viral envelope-directed fusion (Abe et al., 1998).  Indeed, 
we observed that delivery of GFP into mouse BMDCs by GFP-carrying liposomes was 
greatly enhanced if the liposomes were enveloped with VSV-G (Figure 5D).  Additionally, 
maturation of DCs was increased if liposomes were enveloped with VSV-G, suggesting 
that VSV-G-directed fusion was immunostimulatory.  To determine whether VSV-G-
directed fusion induced DC activation via STING, we treated STING-deficient mouse 
BMDCs with VSV-G liposomes and found that DC maturation was unaffected (Figure 
5E).  These results suggest that VSV-G-directed fusion itself induces DC activation in a 
STING-independent manner.  Thus, there appears to be two separate activating 
processes at work when enveloped particles stimulate DCs: one is STING-dependent 
and the other is STING-independent. These findings suggest the STING-independent 
process is activated by envelope protein-directed fusion. What then activates the 
STING-dependent process? It seemed likely that a stimulatory viral component was 
released into the cytoplasm by viral fusion.  
 
Lentiviral particles and VLPs contain human DNA 
We next attempted to identify an immunostimulatory component that might be released 
by LVs or VLPs.  Since STING is involved in cytosolic dsDNA recognition, we suspected 
that LVs and VLPs might contain non-viral DNA.  Indeed, plasmid DNA used during LV 
production has been detected inside LV particles (Pichlmair et al., 2007).  Consistent 
with this work, we amplified plasmid-specific DNA sequences of the VSV-G and 
ampicillin resistance genes in the LV and VLP preparations by PCR.  Interestingly, we 
also amplified DNA sequences for human beta-actin and human Alu repeat element in 
LV and VLP preparations (Figures 6A, S5A, and S5B).  We did not find evidence of 
human DNA in cell-free supernatant collected from 293T cells transfected with a mock 
plasmid (Figures 6A and S5B).  To assess whether the plasmid and human DNA were 
carried within or associated externally to the particles, we pre-treated VLPs with DNase I 
to degrade external DNA, and then inactivated DNase I with EDTA before particles were 
lysed and then analyzed by PCR.  Despite pre-treatment with DNase I, we continued to 
detect plasmid and human DNA in the vector preparations, suggesting plasmid and 
human DNA was contained within the particles (Figure 6B).  We used genomic DNA to 
show DNase I digestion was efficient and DNase I inactivation with EDTA was effective 
(Figure 6C).  We also amplified plasmid and human DNA in the cell-free supernatant of 
293T cells transfected with a plasmid encoding HIV-1 (Figure 6D). Therefore, these 
results suggest that LV, VLP, and infectious HIV-1 particles, which are produced by 
transient transfection of 293T cells, contain both plasmid and human genomic DNA.   
 
To determine whether the presence of DNA in particles was particular to material made 
in 293T cells, we asked whether HIV-1 passaged in human PBMCs also contained 
human genomic DNA.  Interestingly, we were able to amplify human DNA from the cell-
free HIV-1 supernatant collected after passage the virus in human PBMCs (Figures 6E). 
Human DNA was not detected in the cell-free supernatant collected from uninfected 
PBMCs.  In addition, we found that the DNA detected in the passaged cell-free HIV-1 
supernatant was resistant to DNase I (Figure 6F), suggesting that human genomic DNA 
was also encapsulated inside HIV-1 particles. 
 
Human DNA delivered into DCs by VSV-G fusion is immunostimulatory 
We next questioned whether the delivery of plasmid or genomic DNA by viral fusion 
would enhance the DC activation generated by viral fusion itself.  Therefore, we exposed 
mouse BMDCs to empty VSV-G liposomes or VSV-G liposomes carrying plasmid DNA 
or genomic DNA extracted from 293T cells.  As expected, we found VSV-G liposomes 
induced DC maturation (Figure 6G).  The addition of human genomic DNA into VSV-G 
liposomes resulted in even higher levels of DC activation.  We then found that the 
enhancement in DC activation due to human DNA was abrogated in STING-deficient 
BMDCs (Figure 6H).  These results suggest that both viral fusion itself and viral-fusion-
dependent delivery of human DNA are able to induce DC maturation, the former in a 
STING-independent and the latter in a STING-dependent manner. These findings 
provide an explanation for the STING-dependence observed in the innate and adaptive 
immune responses generated by LVs and VLPs.  
 
DISCUSSION 
From our previous work we knew that DC-targeted LVs deliver antigen to DCs and 
stimulate a massive antigen-specific CD8+ T cell response in vivo (Yang et al., 2008), 
which was consistent with previous work demonstrating LVs activate innate and adaptive 
immunity (Granelli-Piperno et al., 2000, He et al., 2005, Dullaers et al., 2006, Esslinger 
et al., 2003).  In the present investigation, we examined why LVs are so effective at 
these processes. We were especially interested in understanding how these vectors 
deliver antigen and provide immune stimulation.  We found that there were four 
components of the virions contributing to the immunization process.  
 First, we found that vector-encoded protein antigen is carried over from the producer 
cells in the vector particles via pseudotransduction. Previous reports of 
pseudotransduction (Haas et al., 2000, Nash and Lever, 2004, Breckpot et al., 2007) 
have not appreciated how effectively this process delivers antigen to differentiated DCs.  
We observed that the in vivo administrations of DC-targeted LV in the presence of RTIs 
and VLP immunization were sufficient in producing antigen-specific CD8+ T cells, 
suggesting LV pseudotransduction alone capably delivers antigen and simulates the 
immune system. 
 
Second, we found that the delivery of the LV genome was important to antigen 
expression, but not immune stimulation.  Mice immunized with a LV encoding GFP and 
carrying the protein OVA (LV-GFPgene-OVAprotein) had similar immune responses to VLP-
OVA immunized mice. These results strongly imply that the viral genome of the LVs, in 
the form of reverse transcribed DNA, encodes antigen and contributes to antigen 
delivery, but not to immune stimulation.  This is consistent with our in vitro results 
showing virtually all of the antigenic stimulation of differentiated DCs is due to 
pseudotransduction because activation is not sensitive to RTIs and efficiently occurs 
with viral genome-deficient vectors.  The cells transduced by our DC-targeting LV in vivo 
may be early stage DCs, which are relatively easier to transduce, but resistant to 
stimulation compared to differentiated DCs (Chinnasamy et al., 2000, Rouas et al., 2002, 
He et al., 2005, Schroers et al., 2000).  The mechanism of how transduced cells 
contribute to antigen delivery has yet to be defined.  Since our data and previous work 
suggest that LV transduction is not stimulatory, it is possible that antigen in transduced 
cells may be indirectly presented or cross-presented to the immune system (He and Falo, 
2007).  Altogether, our results further clarify the role of true LV infection in vivo. 
 Third, we found that the activation of DCs (assayed by the appearance of activation 
marker proteins on the cell surface) was partly a consequence of fusion between the LV 
membrane and the endosomal membrane. We showed that particles must be 
internalized (bald particles were ineffective) and then fused with endosomal membranes 
(active viral fusogen is needed and chloroquine, which inhibits endosome acidification, 
or fusion-defective vectors abolish DC activation). This process did not require STING, 
an endoplasmic reticulum-resident protein and adaptor protein for cytosolic DNA 
detection pathways.  
 
Fourth, we investigated what other mechanisms might be involved in DC activation.   By 
using various knockouts, we found that neither a TLR nor RIG-I was involved.  Rather, 
DC activation was partially dependent on STING.  Our study identified cellular DNA 
packaged from producer cells as the component of the virion that is sensed by STING.  
This is consistent with previous reports showing cytosolic dsDNA is a well-known 
activator of innate immunity through STING (and cyclic GMP-AMP synthase (cGAS)) 
(Gao et al., 2013, Jakobsen et al., 2013).  Thus, the fourth component of the virion that 
contributes to LV immunization is encapsulated human DNA.  Current work is underway 
to examine the role of cGAS, which recognizes cytosolic dsDNA and signals upstream of 
STING (Sun et al., 2013).   
 
Our study sheds new light the mechanism of DC vaccination by LVs.  We have found 
that antigen delivery is an additive process between LV pseudotransduction and 
transduction.  However, LV immune stimulation is induced primarily by LV 
pseudotransduction.  We had expected that TLR or RIG-I activation of innate immune 
responses was important based on previous work suggesting the importance of MyD88 
and TRIF in DC activation in vitro and in vivo (Breckpot et al., 2007, Pichlmair et al., 
2007).  However, we found that neither TLR nor RIG-I signaling was involved.  Rather, 
activation was partially dependent on STING. The differing results of our study may be 
because we injected a DC-targeted LV into mice to determine the direct effects of LVs 
on DCs in vivo. Previous work used adoptive transfer experiments to infer the in vivo 
effect of LVs on DC activation (Breckpot et al., 2007, Pichlmair et al., 2007).   In addition, 
we found viral fusion itself and viral-fusion-dependent delivery of human DNA induced 
DC maturation, the former in a STING-independent and the latter in a STING-dependent 
manner.  One group has also observed that STING was required to generate type I 
interferon responses to the fusion (Holm et al., 2012) by herpes VLPs and cationic 
liposomes.  Herpes VLPs have different mechanisms of entry compared to our VSV-G 
and SVGmu-pseudotyped VLPs. Additionally, the mechanism of entry of cationic 
liposomes is not fully elucidated is not fully elucidated and does not follow classical 
fusion utilized by enveloped viruses (Elouahabi and Ruysschaert, 2005).  Thus, we used 
VSV-G enveloped liposomes to study viral fusion itself. 
 
Our findings raise important questions regarding the nature of particles in virus 
preparations. Previous work has suggested that HIV particles passaged in T cells are a 
mixture of replication-competent and replication-defective particles, the latter being more 
abundant (Bernier and Tremblay, 1995).  In addition, the expression of glycoproteins of 
vesicular stomatitis virus and Sindbis virus in 293T producer cells results in the 
spontaneous shedding of enveloped particles (Moore et al., 2006, Mangeot et al., 2011).  
Thus, we suspect that virus preparations contain a mixture of particles with and without 
the viral RNA genome. We are uncertain whether only one or both types of particles 
contain the protein and cellular DNA that are involved in DC stimulation and T cell 
response. Separation of the various types of particles has been difficult, but with the 
improvement and accessibility of single nanoparticle sorting, the answers to these 
questions are now within our reach. 
 
In addition, we assume that the vector-encoded protein contained in the viral particles is 
merely encapsulated cytoplasm because we found both OVA and GFP in the particles. 
However, there may be more specific interactions involved. How DNA is packaged within 
particles is more of a mystery. HIV infection induces cell death by pyroptosis, a process 
that leads to DNA fragmentation (Doitsh et al., 2014).  It could be that as cells die, the 
HIV particles being produced pick up fragmented DNA from the host cell.  We also 
detected human genomic DNA within LV and VLP particles, the formation of which 
should not involve pyroptosis.  The ability of LVs and VLPs to package human genomic 
DNA may be a result of liposomal transfection reagents, which are cyto- and genotoxic, 
inducing host DNA damage and increasing cytosolic dsDNA in cells (Knudsen et al., 
2015, Shen, 2014).  Thus, the fragmented, cytoplasmic genomic DNA may be available 
for encapsulation in many cell types via different processes. Further studies are needed 
to determine the immunologic significance of human genomic DNA delivered by viral 
particles.   
This study began as an investigation of a particular form of technology, DC-targeted LV.  
As the work has progressed, aspects of viral interaction with host immunity have 
become evident and that have helped to understand the transduction process but have 
raised multiple questions about what is delivered by viral vectors.  Our findings suggest 
that cellular DNA may act as a viral ligand to the STING pathway. The development of 
DNA adjuvants that serve as STING agonists could provide a new therapeutic strategy 
for inducing CD8+ T cell responses. Additionally, our finding that lentiviral vectors 
package tumor cell DNA from producer cells raises a potential safety concern for viral 
vector-based gene therapies, which merit further investigation.  
  
EXPERIMENTAL PROCEDURES 
 
Statistics, sample size selection, and exclusion criteria. All experimental group sizes 
were selected to ensure adequate statistical power despite the variable nature of the 
studies performed. No animals were excluded from the study. Groups of animals were 
chosen in consecutive order and were not randomized prior to commencing the study.  
Animal studies were not performed in a blinded fashion. 
 
Mice. C57BL/6J, MyD88-/-, TRIF mutant (C57BL/6J-Ticam1Lps2), Tmem173-/-, and OT-I 
(C57BL/6-Tg(TcraTcrb)1100Mjb/J) mice were obtained from The Jackson Laboratory.  
IPS-1-/- mice were provided by G. Cheng (UCLA).  MyD88-/-/Ticam1Lps2/Lps2 and MyD88-/-
/IPS-1-/- mice were generated and bred.  p50-/- mice have been described (Sha et al., 
1995).  All mice were maintained on the C57BL/6J background and used according to 
protocols approved by Institutional Animal Care and Use Committee at Caltech.  
Experiments were performed with mice 6-12 weeks of age with sex-matched littermates. 
 
Antibodies and flow cytometry. Single-cell suspensions were stained with the 
following antibodies from Biolegend: Pacific blue-anti-mouse CD11b (117321), pacific 
blue-anti-mouse CD44 (103020), PE-anti-mouse CD62L (104408), PE-anti-human 
CD11c (301606), PE/Cy7-conjugated anti-mouse I-Ab (115420), PE/Cy7-anti-mouse 
CD69 (104512), PerCP-anti-human CD14 (325621), APC-anti-mouse CD11c (11730), 
APC-anti-human CD86 (305411), APC/Cy7- anti-mouse CD86 (105030), and APC/Cy7-
anti-human HLA-DR (307617). For dead cell staining, 1ug ml-1 of propidium iodine was 
added.  APC-conjugated H-2Kb tetramers bound to the OVA-derived peptide SIINFEKL 
were obtained from the NIAID Tetramer Facility. Cells were analyzed on a MACSQuant 
analyzer (Miltenyi), data were analyzed with FlowJo software (TreeStar). 
 Isolation and culture of DCs. Differentiation of mouse BMDCs was achieved by culture 
for 8 d in media containing granulocyte-macrophage colony-stimulating factor (GM-CSF) 
(1:25 J558L conditioned medium) as previously described (Dai et al., 2009).  Human 
moDCs were generated by culture for 8 d of CD14+ peripheral blood monocytes (UCLA 
Center for AIDS Research (CFAR) Virology Core Lab) in media containing human GM-
CSF and IL-4 (Peprotech). BMDCs and moDCs were cultured in RPMI-1640 medium 
supplemented with 10% (vol/vol) fetal bovine serum (FBS) (Sigma), 1% (vol/vol) non-
essential amino acids (HyClone), 1mM sodium pyruvate (Gibco), 10mM HEPES (Gibco), 
and 0.05mM 2-mercaptoethanol (Gibco).   
 
Cell lines. HEK293T/17 cells (ATCC) and 293T.DCSIGN cells, which were generated as 
previously described (Yang et al., 2008), were cultured in DMEM with 10% (vol/vol) FBS. 
EL4 (C57BL/6J, H-2b, thymoma) and E.G7 (EL4 cells stably expressing one copy of 
chicken OVA cDNA) provided by L. Yang (UCLA) and GXR.CEM human lymphoblastoid 
CD4+ T cells provided by B. Walker (Ragon Institute) were cultured in RPMI-1640 
medium with 10% (vol/vol) FBS. All media was supplemented with 1% (vol/vol) penicillin 
and streptomycin (Gibco).  
 
LV, VLP, and infectious HIV-1. The LV transfer vectors (FUGW, FOVA) used in this 
study are the third generation HIV-based LVs. FUGW encodes the GFP and FOVA 
encodes an invariant chain-OVA fusion construct as previously described (Hu et al., 
2011). The plasmids pMDLg/pRRE encoded gag and pol and pRSV-Rev encoded rev.  
The envelope plasmids used were p.VSV-G and p.SVGmu (Yang et al., 2008).  
Introducing mutations G124A and P127A as previously described (Zhang and Ghosh, 
1994) generated the fusion-defective VSV-G. The pNL4-3 plasmid used to generate 
infectious HIV-1 was obtained from the AIDS Reagent Program, Division of AIDS, NIAID, 
NIH.  Virus was prepared by culturing HEK293T/17 cells in 10-cm tissue culture dishes 
and transfecting with BioT (Bioland Scientific, Paramount CA) according to 
manufacturer's instructions using a total of 10 µg DNA.  For production of LV, we used 
the LV transfer vector plasmid, which encodes the viral genome (4 µg), and 2 µg each of 
the packaging plasmids (pMDLg/pRRE, pRSV-Rev), and the envelope plasmid (VSVG, 
SVGmu, VSVG.fd). LV encoding GFP used the LV transfer vector plasmid FUGW and 
LV encoding OVA used the LV transfer vector plasmid FOVA.  To generate LV encoding 
GFP and carrying OVA, the plasmids FUGW, pMDLg/pRRE, pRSV-Rev, p.SVGmu, and 
an expression plasmid encoding the invariant chain-OVA fusion construct (p.OVA) were 
used.  To generate VLPs lacking a viral genome, the LV transfer vector plasmid was 
omitted.  Capsid deficient vectors were generated by omitting the packaging plasmids 
pMDLg/pRRE and pRSV-Rev.  Consistent with previous findings, transfection of 293T 
producer cells with the LV packaging plasmids encoding gag, pol and rev generated 
“bald” particles (Cowan et al., 2002). To generate VLPs carrying GFP or OVA, an 
expression plasmid encoding GFP (p.GFP) or p.OVA was included during transfections. 
Puc19 plasmid was transfected into 293T cells as a negative control.  To generate an 
infectious molecular clone of HIV-1, 20 µg of pNL4-3 plasmid was used for transfections.  
All viral supernatants were harvested at 36, 48, and 60 h post-transfection and filtered 
through a 0.45-µm filter.  The cell-free LV and VLP supernatants were additionally 
ultracentrifugated (Optima L-80 K preparative ultracentrifuge, Beckman Coulter) at 
80,000 g for 90 min through a 20% (vol/vol) sucrose cushion. The pellets were then 
resuspended in an appropriate volume of cold PBS. 293T and 293T.DCSIGN cells were 
infected with LV and cells analyzed for GFP expression by flow cytometry to determine 
the transduction titer by the dilution ranges that exhibited a linear response. The 
concentration of gag was measured by p24 capture ELISA Kit (ImmunoDiagnostics) and 
GFP by GFP ELISA Kit (Abcam).  The concentration of iOVA was determined using a 
sandwich ELISA.  The 96-well plates were coated with anti-CD74 at 5 µg ml-1 (555317; 
BD Biosciences) and blocked with PBS containing 1% (vol/vol) BSA.  The vectors were 
lysed in 0.5% (vol/vol) Triton X-100 and incubated on coated plates.  The amount of 
captured OVA was determined using anti-chicken OVA at 5 µg ml-1 (1221; Abcam).  
Detection was performed using a horseradish peroxidase-conjugated goat-anti-mouse 
IgG (Bethyl Lab) at a dilution of 1:10,000. Colorimetric analysis was performed using 
TMB Peroxidase Substrate System (KPL) and absorbance was read at 450nm.  
 
DC treatment with vectors. DCs (1–2 × 106 cells) were centrifuged with LV (1–2 × 106 
transduction units; 100–200 ng of p24, GFP, or OVA) or VLP (100–200 ng of p24; 100–
200 ng of GFP) at 1,050 g at 30 °C for 90 min.  After centrifugation, the supernatant was 
removed and replaced with fresh medium and cytokines and incubated at 37 °C with 5% 
of CO2. Post-treatment, the supernatant was removed and replaced with fresh medium 
containing cytokines and incubated at 37 °C with 5% of CO2. Cycloheximide (CHX) and 
chloroquine (CQ) (Sigma) were added to cell cultures 1 h prior to LV treatment and was 
added back to the fresh medium. Tenofovir (TFV) and efavirenz (EFV) (AIDS Research 
and Reference Reagent Program, NIAID/NIH) were added to cell cultures 6 h prior to LV 
treatment and after centrifugation drugs were added to the fresh media. 
 
Mouse immunization and tumor challenge. LVs and VLPs were injected 
subcutaneously into the right flank of mice. Priming immunization contained between 25-
–50 ng of p24.  All vectors were normalized to equivalent amounts of OVA and/or p24 by 
ELISA.  During prime-boost immunization, the vector doses of the prime and boosts 
were identical.  Blood was collected from the immunized mice and PBMCs processed 
and analyzed for the presence of OVA-specific T cells using a Class I H-2Kb-SIINFEKL 
tetramer and their surface activation markers using flow cytometry.  For homologous 
boosts, mice received the same dose of LV and VLP in the right flank.  Unimmunized 
mice received equal volume injections of PBS. For the tumor protection experiments, 
mice received 1–5×106 EL4 or E.G7 cells injected subcutaneously into the opposing 
flanks of the mice. Tumor size was measured and shown as a product of the two largest 
perpendicular diameters a × b (mm2). In these experiments, the mice were killed when 
the tumors reached 200 mm2.  In the experiments using reverse transcriptase inhibitors 
(RTIs) in vivo, tablets containing efavirenz 600 mg, emtricitabine 200 mg, and tenofovir 
disoproxil fumarate 300 mg were crushed, resuspended in PBS containing 1% (vol/vol) 
DMSO, filtered through a 0.22 µm filter, and stored in aliquots at –80 °C.  RTIs were 
added to the fresh drinking water of mice at the following approximate concentrations: 
efavirenz 10mg ml-1, emtricitabine 3.6 mg ml-1, tenofovir 5.4mg ml-1.  Fresh water 
containing RTIs was replaced two times a week. Mice receiving no RTIs were given 
similar volumes of drinking water and replaced accordingly. Mice were initiated on the 
oral regimen of RTIs one week prior to immunization and continued throughout the 
duration of the experiment. 
 
Immunoblot analysis. Vector preparations were lysed in 1% Triton X-100 in PBS 
supplemented with HALT protease and phosphatase inhibitor cocktail (Life 
Technologies) and clarified by centrifugation. Aliquots of the lysate were mixed with non-
reduced Laemmli's sample buffer and resolved by 5–15% (wt/vol) SDS-PAGE. After 
transfer to nitrocellulose, the following antibodies were used: GFP (8334; Santa Cruz), 
OVA (1221; Abcam), VSVG (v5507; Sigma), and p24 (10R-H120b; Fitzgerald). To 
determine if proteins were inside the vector particles, samples were pre-treated with 
proteinase K 10 µg ml-1 (Qiagen) and incubated at 55 °C for 1 h, and then the proteinase 
K was inactivated with PMSF 1mM (Sigma) before samples were lysed. 
 In vitro DC stimulation of OT-1 cells. Mouse BMDCs were spin-infected with VLPs 
carrying OVA, and washed and resuspended in fresh media and 1 µg ml-1 LPS). CD8+ T 
cells were purified using MACS Columns (Miltenyi) from the spleen cells of OT-1 
transgenic mice and cultured with the uninfected or VLP-infected BMDCs at a ratio of 1:1. 
The cells were collected and analyzed for their surface activation markers using flow 
cytometry 24 h after co-culture. Splenocytes were collected from STING-deficient and 
wild-type mice and treated with PMA (50 ng ml-1) and Ionomycin (500 ng ml-1) for 24h, 
48h, and 72 h.  Cells were then collected and analyzed for their surface activation 
markers using flow cytometry. 
 
Fluorescent imaging. Cells were washed once with cold PBS and then fixed using 4% 
(vol/vol) cold paraformaldehyde in PBS (10 min at 22 °C) followed by washing 4 times 
with cold PBS.  Images were collected using a fluorescence microscope (Axiovert 200m; 
Zeiss) equipped with three filter wheels (Lambda 10-3; Sutter Instruments), and a cooled 
CCD camera (Evolution/Qimaging; Media Cybernetics). Images were collected using 
Image-ProPlus 5.1 software (Media Cybernetics).  All data within each experiment were 
collected at identical imaging settings; relevant sets of images were adjusted only for 
brightness/contrast. 
 
Liposomes. Multilamellar liposomes were prepared based on the conventional 
dehydration-rehydration method as previously described (Liu et al., 2014). DOPC, 
DOPG and MPB-PE (NOF Corporation) were combined in chloroform, at a molar lipid 
ratio of DOPC:DOPG:MPB = 4:1:5, and the organic solvent in the lipid mixture was 
evaporated under argon gas. The lipid mixture was further dried under vacuum overnight 
to form dried thin lipid films. The resultant dried film containing 1.12 ug of lipids was 
hydrated in 10 mM Bis-Tris propane at pH 7.0 with GFP (STA-201; Cell Biolabs) at a 
concentration of 125 ng ml-1 in a total volume of 300ul.  Polyhistidine tagged VSV-G was 
expressed and purified from a suspension 293-E cells after a 48-h transfection using Ni-
NTA column purification. Purified VSV-G protein (200 µg ml-1) was added to the lipid 
hydration mixture before sonication.  Alternatively, 5 ml of VSV-G enveloped VLPs, 
collected from the medium of 293T cell transfected with p.VSVG and purified and 
concentrated as described above, was added to the lipid hydration mixture, as 
previously described (Abe et al., 1998), and DNA was not detectable by PCR in the 
liposomes made by this method.  To add DNA into the liposomes, 30 µg ml-1 of genomic 
DNA extracted from 293T cells or plasmid DNA was added to the lipid hydration mixture. 
Lipid film and hydration mixture were vigorously vortexed every 10 min for 1 h, and then 
applied with 4 cycles of 15 s sonication (Misonix Microson XL2000) on ice in 1 min 
intervals for each cycle.    To induce divalent-triggered vesicle fusion, MgCl2 was added 
at a final concentration of 10 mM. The resulting multilamellar vesicles were further cross-
linked by addition of Dithiothreitol (Sigma) at a final concentration of 1.5 mM for 1 h at 
37 °C. The resulting vesicles were collected by centrifugation at 14,000 g for 4 min and 
then washed twice with PBS.  
 
DNA analysis. Virus and VLP samples were inactivated/lysed by heating to 95 °C for 15 
min. To determine whether DNA was carried within the particles, virus and VLP samples 
were pre-treated with DNase I (Sigma) at a final concentration of 0.1 mg ml-1 at room 
temperature for 10 min, and then the DNase I was inactivated with EDTA 0.625 mM at 
70 °C for 10 min, before inactivation/lysis.  To show that DNase I degradation was 
complete, DNase I was not inactivated by EDTA prior to lysis. PCR amplifications from 
samples were carried out in 0.2-mL thin-walled reaction vessels in the Eppendorf 
Mastercycler proS. The manufacturer-supplied reaction buffer of REDExtract-N-Amp 
PCR ReadyMix (Sigma) was used at concentration of 1× in 25 µl reaction mixtures per 
manufacturer instructions to obtain readily visible PCR products after 35–40 
amplification cycles (30 s at 95 °C, 30 s at 50 °C and 1 min at 72 °C).  The following 
primer sequences were used for identification of DNA:  VSV-G 5’-
TGAAGTGCCTTTTGTACTTAGCCTTTTTATTC-3’ and 5’- 
ACCAGCGGAAATCACAAGTAGTGACC-3’; ampR 5’-
AATCAGTGAGGCACCTATCTCAGCG-3’ and 5’-AAGCCATACCAAACGACGAGCG-3’; 
AluYd6 (human), 5’ GAGATCGAGACCACGGTGAAA-3’ and 5’-
TTTGAGACGGAGTCTCGTT-3’ as previously described (Walker et al., 2003); ACTB 
(human), 5’- CATGTACGTTGCTATCCAGGC-3’, and 5’-ATTACCCACTCCCGACCCG 
(Primerbank ID 4501885a1).  The amplification products were electrophoresed on 2% 
(wt/vol) agarose gel with subsequent ethidium bromide staining.  
 
HIV passaging. Anonymous human PBMCs were provided by the UCLA Center for 
AIDS Research (CFAR) Virology Core Lab (peripheral blood). PBMCs were cultured in 
5 µg ml−1 PHA (Sigma) in the presence of 5 ng ml−1 IL-2 (Peprotech) cells at 1 × 106 cells 
ml-1 and infected with 50 ng p24 of NL4-3 virus supernatant and incubated at 37 °C for 1 
d.  Infected cells were washed and and incubated again at 37 °C for 2 d.  Uninfected 
cells were concurrently treated in an identical manner.  Cell-free supernatant was 
collected and filtered through a 0.22 µm filter.  Aliquots of cell-free supernatants were 
stored at –80 °C.  All work was approved by the California Institute of Technology 
Institutional Biosafety Committee and Institutional Review Board exempt. 
 
Statistical Analyses. GraphPad Prism 6.0 software was used for data analysis.  
Statistical significance was determined by unpaired, two-sided Student’s t-tests for two 
groups or one-way ANOVA (with post-hoc Tukeys’ multiple comparison test) for three or 
more groups.  
 
  
FIGURE LEGENDS 
Figure 1. Lentivector (LV) pseudotransduction delivers proteins and stimulates 
dendritic cells (DCs).   
(A) Mouse bone marrow-derived DCs (BMDCs), human monocyte-derived DCs 
(moDCs), and 293T cells were incubated with tenofovir (TFV) 40 µM, efavirenz (EFV) 80 
µM, or no drug (ND) 6 h prior to treatment with VSV-G-pseudotyped LV expressing GFP 
(LV-GFP(V)), and then analyzed 24 h later for GFP expression by flow cytometry.  
(B) GFP mean fluorescent intensity (MFI) of DCs as treated in A.   
(C) Mouse BMDCs were incubated with or without cycloheximide (CHX) for 1 h prior to 
treatment with LV-GFP(V) and GFP MFI measured by flow cytometry over 4 h. Results 
are presented relative to those of BMDCs receiving no LV with or without CHX.   
(D) Western blot analysis of GFP of vector lysates from LV-GFP(V) and LV expressing 
ovalbumin (OVA) pseudotyped with VSV-G (LV-OVA(V)) and 40ng of purified GFP 
protein. Analysis of VSV-G was used as a loading control for the vectors.  
(E,F) mouse BMDCs (E) and human moDCs (F) were treated as in A and analyzed for 
activation by measuring the MHC II molecule I-Ab and/or CD86 by flow cytometry. 
n.s.=not significant with P > 0.05; ***P < 0.001 (unpaired Student’s t-test (B,D,F)). Data 
are representative of at least two independent experiments (A,B,D-F) or three 
independent experiments (C). Results are shown as mean ± s.e.m of technical replicates 
(B,C,E).  See also Figure S1. 
  
Figure 2. LV DNA, genome, and capsid are not required for DC maturation and 
CD8+ T cell priming.   
(A,B) Schematic diagram of VLPs and corresponding Western blot analysis for GFP, 
VSV-G, and p24 on LV and VLP lysates.  
(C,D,E) Mouse BMDCs and human moDCs were treated with VSV-G or SVGmu-
pseudotyped LVs and VLPs and then analyzed at 24 h for GFP, CD86, and I-Ab or HLA-
DR expression by flow cytometry.  
(F-I) Wild-type mice received homologous prime-boost vaccination of SVGmu-
pseudotyped LV expressing OVA (LV-OVA) with or without RTI or SVGmu-pseudotyped 
VLP carrying OVA (VLP-OVA).  (F) Flow cytometry analyzed the frequency of OVA-
specific tetramer (H-2Kb-SIINFEKL)+ CD8+ T cells from the blood at 7 and 10 d post-
primary immunization.  Numbers adjacent to outlined areas indicate percent of tetramer+ 
cells among the total CD8+ T cells. (G) Tetramer+ CD8+ T cells from the blood of 
immunized and unimmunized mice were measured by flow cytometry (black arrow, 
boost.  (H) Flow cytometry analyzed CD62L and CD44 expression of tetramer+ CD8+ T 
cells from immunized mice compared or naïve CD8+ T cells from unimmunized mice at 
41 d. (I) Seven wk post-boost, mice were injected with OVA-expressing and control 
tumor cells on opposing legs and tumor sizes measured.   
(J,K) Wild-type mice were homologously prime-boosted with LV-OVA, VLP-OVA, or VLP 
without capsid carrying OVA (VLP-OVAΔgag).   (J) Tetramer+ CD8+ T cells were 
measured from the blood. (K) Mice were injected with tumor cells as in I.   
(L) Wild-type mice were injected with LV-OVA, LV encoding OVA carrying GFP (LV-
GFPgene-OVAprotein), or VLP-OVA.  Tetramer+ CD8+ T cells were measured from the blood.   
n.s.=not significant with P > 0.05; *P < 0.05; ***P < 0.001 (unpaired Student’s t-test 
(C,D)). Data are representative of two independent experiments (B-E; mean ± s.e.m. of 
technical replicates in C-E), one experiment (G-I; mean ± s.e.m. of n = 8 mice per group 
in E,G,H-J), or representative of two independent experiments (J-L; mean ± s.e.m. of n = 
8 mice per group).  See also Figure S2. 
 
Figure 3. LV activation of DCs and subsequent CD8+ T cell priming is dependent 
on STING, but not MyD88, TRIF, or IPS-1.  
(A) BMDCs from mice deficient in MyD88, TRIF, and IPS-1 were treated with LV-GFP(V) 
or LV-GFP(S) and analyzed at 24 h for expression of CD86 and I-Ab by flow cytometry. 
(B-D) Mice deficient in MyD88, TRIF, IPS-1, or STING were immunized with LV-OVA. 
(B) Flow cytometry analyzed the frequency of OVA-specific tetramer+ CD8+ T cells from 
the blood at 10 d post-immunization. Numbers adjacent to outlined areas indicate 
percent of tetramer+ cells among the total CD8+ T cells.  (C) Tetramer+ CD8+ T cells from 
the blood of immunized mutant and wild-type mice or unimmunized wild-type mice (n = 6 
mice per group).  Values between the groups of immunized mutant and wild-type mice at 
10 d showed no statistical significance.  (D,E) CD62L and CD44 expression of tetramer+ 
CD8+ T cells from immunized wild-type and mutant mice compared to naïve CD8+ T cells 
from unimmunized wild-type mice at 10 d (n = 6 mice per group).   
(F) Tetramer+ CD8+ T cells from the blood of immunized STING-deficient and wild-type 
mice (n = 5 mice per group).  
(G) CD62Llo and CD44+ tetramer+ CD8+ T cells from STING-deficient and wild-type mice 
at 10 d (n = 5 mice per group).   
Each symbol (C,E) represents the mean; error bars indicate s.e.m. Each symbol (E,G) 
represents an individual mouse; small horizontal lines indicate the mean.  n.s., not 
significant, P > 0.05 (one way-ANOVA (A,C,E)); *P < 0.05 (unpaired Student’s t-test (f)). 
Data are from one experiment representative of three independent experiments (A; 
mean and s.e.m.), two independent experiment (B-E), or pooled from two experiments 
(F,G).  See also Figures S1, S3, and S4. 
 
Figure 4. Viral-like particles (VLPs) activate DCs and antigen-specific CD8+ T cells 
via the STING pathway.  
(A) BMDCs from STING-deficient and wild-type mice were treated with VLP carrying 
GFP pseudotyped with VSV-G (VLP-GFP(V)) or SVGmu (VLP-GFP(S)) and analyzed at 
24 h for CD86 and I-Ab expression by flow cytometry.  
(B) STING-deficient and wild-type BMDCs were treated with VLP-OVA pseudotyped with 
VSV-G (VLP-OVA(V)) or SVGmu (VLP-OVA(S)) and then cocultured with OT-1 CD8+ T 
cells for 24 h. The CD8+ T cells were analyzed for expression of activation markers 
CD69 and CD25 by flow cytometry.  
(C-E) STING-deficient and wild-type mice were homologously prime-boosted with 
SVGmu-pseudotyped VLP-OVA.  (C) Flow cytometry analyzed the frequency of OVA-
specific tetramer+ CD8+ T cells from the blood at 7 d post-boost. Numbers adjacent to 
outlined areas indicate percent of tetramer+ cells among the total CD8+ T cells.  (D) 
Tetramer+ CD8+ T cells from the blood of immunized STING-deficient and wild-type mice 
and unimmunized wild-type mice measured (black arrow, boost); (n = 8 mice per group). 
(E) CD62Llo and CD44+ tetramer+ CD8+ T cells from STING-deficient and wild-type mice 
at 7 d post-boost (n = 8 mice per group).  
Each symbol (D) represents the mean; error bars indicate s.e.m. Each symbol (E) 
represents an individual mouse; small horizontal lines indicate the mean. n.s., not 
significant, P > 0.05; *P < 0.05; **P < 0.005; ***P < 0.001 (unpaired Student’s t-test 
(A,B,E)). Data are from one experiment representative of three independent experiments 
(A; error bars indicate s.e.m.), two independent experiments (B; error bars indicate 
s.e.m.), or pooled from two independent experiments (C-E).  
 
Figure 5. Viral fusion is required for DC activation.  
(A) Mouse BMDCs were incubated with chloroquine (CQ) at 25 µM, 75 µM, 100 µM 
(wedges) or no drug (ND) 1 h prior to treatment with LV or VLPs, and analyzed at 24 h 
for CD86 and I-Ab expression by flow cytometry.  
(B) Fluorescence microscopy of mouse BMDCs treated with fusion-competent VLP-
GFP(V) with or without CQ or fusion-defective VLP-GFP(V.FD).  400× magnification 
scale bar = 10 µm.  
(C) Mouse BMDCs were infected with fusion-competent or fusion-defective LVs or VLPs 
carrying GFP and analyzed for CD86 and I-Ab expression.  
(D,E) BMDCs from wild-type and STING-deficient mice were treated with naked (Lipo) or 
VSV-G enveloped multilamellar liposomes (Lipo(V)) carrying GFP and analyzed at 24 h 
for CD86 and I-Ab expression.  
n.s., not significant, P > 0.05; ***P < 0.001 (unpaired Student’s t-test (C,D,E)). Data are 
from one experiment representative of three independent experiments (A,C,D; error bars 
indicate s.e.m.) or two independent experiments (B,E; error bars indicate s.e.m.). 
 
Figure 6. LV particles and VLPs contain human genomic DNA recognized by the 
host STING pathway.  
(A) Amplicons of human β-actin (ACTB) and the ampicillin resistance gene (amp) 
detected in the LV and VLP preparations by PCR. The cell-free supernatant collected 
from 293T cells transiently transfected with mock plasmid puc19 was used as a negative 
control.   
(B) Amplicons of human Alu element (Alu) and VSV-G (VSIVgp4) were amplified from 
VLP preparations or genomic DNA (lane 1). VLP preparations or genomic DNA was 
treated with DNase I leading to DNA degradation (lane 2).  If the DNase I was 
inactivated with EDTA before lysis, then DNA continued to be detected (lane 3). DNase I 
was inactivated with EDTA, and then VLP lysate added to show DNase I was effectively 
inactivated (lane 4).   
(C) Amplicons of human DNA from 293T cellular genomic DNA treated in the same 
conditions as in B.   
(D) PCR analysis for amplicons of human ACTB and Alu and plasmid from cell-free 
supernatant collected from 293T cells transiently transfected with the plasmid p.NL4-3 
encoding infectious HIV-1 or 293T genomic DNA.  
(E) NL4-3 HIV-1 was passaged in primary PBMCs and the cell-free supernatant was 
collected and analyzed for human ACTB.  As a negative control, cell-free supernatant 
was collected from uninfected PBMCs.   
(F) Amplicons of human ACTB and Alu were detected in cell-free supernatant containing 
NL4-3 HIV-1 passaged in primary PBMCs (lane 1). HIV-1 supernatant was treated with 
DNase I (lane 2), and then DNase I was inactivated by EDTA (lane 3) before lysis.  
DNase I was inactivated with EDTA and HIV lysate added to show DNase I was 
effectively inactivated (lane 4).   
(G,H) BMDCs from STING-deficient or wild-type mice were treated with naked (Lipo) or 
VSV-G-enveloped multilamellar liposomes carrying plasmid DNA (Lipo-plasmid(V)), 
genomic DNA extracted from 293T cells (Lipo-gDNA(V)), or nothing (Lipo(V)).  Cells 
were analyzed 24 h post-treatment for CD86 and I-Ab expression by flow cytometry.   
n.s., not significant, P > 0.05; *P < 0.05; ***P < 0.001 (unpaired Student’s t-test (G,H)).  
Data are from one experiment representative of three independent experiments (A-F) or 
two independent experiments (G,H; error bars indicate s.e.m.).  See also Figure S5. 
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SUPPLEMENTAL FIGURE LEGENDS 
Figure S1. LVs pseudotransduce and activate mouse BMDCs, related to Figures 1 and 3.  
Mouse BMDCs were treated with LV-GFP(V), LV-GFP(S), LPS, or no vector (NV) and analyzed 
for expression of GFP, CD86, and I-Ab by flow cytometry.  
(A) Numbers adjacent to outlined areas are the GFP MFI values of the CD11c+CD11b+ cells 
immediate post-LV treatment.   
(B) Numbers adjacent to outlined areas are the percent activated CD11c+CD11b+ cells.  
(C, D) Time course of the expression of GFP, CD86+ and I-Ab+ BMDCs over 48 h. Each symbol 
represents the mean; error bars indicate s.e.m. Data are from (A) one experiment representative 
of five independent experiments or from two independent experiments (B-D).  See also Figures 1 
and 2. 
 
Figure S2. LVs and VLPs carry heterologous proteins, related to Figure 2.  
(A) Western blot analysis of GFP and VSV-G from the viral lysates of LV-GFP(V) and LV 
expressing ovalbumin (OVA) pseudotyped with SVGmu (LV-OVA(S)).   
(B) Western blot analysis for GFP or OVA from the viral lysate of VSVG or SVGmu-pseudotyped 
VLPs carrying GFP or OVA.  
(C) Western blot analysis of OVA in the lysate of SVGmu-pseudotyped VLP carrying OVA.  VLP 
carrying OVA was not treated with proteinase K (PK) or PMSF (lane 1). VLP was pre-treated with 
PK, and then the PK was inactivated with PMSF before lysis (lane 2). To verify PK degradation 
was effective, PK was not inactivated before VLP lysis (lane 3).  See also Figure 1. 
 
Figure S3. MyD88-/-/TRIFLps2/Lps2 or MyD88-/-/IPS-1-/- BMDCs are fully activated by LVs, 
related to Figure 3. 
(A,B) BMDCs from mice doubly deficient in MyD88 and TRIF (A) or MyD88 and IPS-1 (B) were 
treated with LV-GFP(V) or LV-GFP(S) and analyzed 24 h post-treatment for the percentage of 
CD86 and I-Ab-positive cells by flow cytometry. n.s., not significant, P > 0.05 (unpaired Student’s 
t-test).  Data from three independent experiments (mean and s.e.m.).  See also Figure 3. 
 Figure S4. Normal T cell subsets in STING-deficient mice under non-stimulatory conditions, 
related to Figure 3. 
(A, B) Splenocytes from STING-deficient or wild-type mice were analyzed by flow cytometry using 
anti-CD4 and anti-CD8 under non-stimulated conditions.   
(C) Wild-type and STING-deficient splenocytes were treated with PMA (50ng/ml) and ionomycin 
(500ng/ml) and cells were analyzed at 24 h, 48 h, and 72 h post-treatment.  Surface expression 
of CD69 and CD25 of the gated CD8+ T cells was measured by flow cytometry. n.s., not 
significant, P > 0.05 (unpaired Student’s t-test).  Data from two independent experiment (mean 
and s.e.m) (A-C).  See also Figure 3. 
 
Figure S5. LV particles and VLPs contain human genomic DNA, related to Figure 6. 
(A,B) Amplicons of  VSV-G (VSIVgp4) and human Alu repeat element (Alu) in the LV and VLP 
preparations by PCR. See also Figure 5. 
  
FIGURES 
 
Figure 1. Lentivector (LV) pseudotransduction delivers proteins and stimulates 
dendritic cells (DCs).   
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Figure 2. LV DNA, genome, and capsid are not required for DC maturation and 
CD8+ T cell priming.  
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 Figure 3. LV activation of DCs and subsequent CD8+ T cell priming is dependent 
on STING, but not MyD88, TRIF, or IPS-1.  
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Figure 4. Viral-like particles (VLPs) activate DCs and antigen-specific CD8+ T cells 
via the STING pathway.  
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 Figure 5. Viral fusion is required for DC activation.  
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 Figure 6. LV particles and VLPs contain human genomic DNA recognized by the 
host STING pathway.  
  
Figure S1. LVs pseudotransduce and activate mouse BMDCs, related to Figures 1 
and 3.  
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Figure S2. LVs and VLPs carry heterologous proteins, related to Figure 2. 
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by LVs, related to Figure 3. 
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Figure S4. Normal T cell subsets in STING-deficient mice under non-stimulatory 
conditions, related to Figure 3. 
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Dendritic cell-to-T cell transmission of HIV is a drug-insensitive mode of infection.  In 
preparation. 
  
ABSTRACT 
Cell-to-cell transmission of HIV-1 allows for a high amount of concentrated virus to be 
directed to uninfected target T cells, which overwhelms the capacity of anti-retroviral 
drugs.  During dendritic cell (DC)-to-T cell transmission, uninfected DCs can concentrate 
infectious virions and transmit them to T cell targets via cellular contacts.  Here, we 
report DCs amplify the efficiency of T cell infection, which results in anti-retroviral drug 
insensitivity compared to T cell infection in the absence of DCs.  The DC-mediated 
amplification and drug-insensitivity of T cell infection are both entirely dependent on 
physical cellular interactions.  Further, we find the input of virus is important to the drug 
insensitivity of DC-to-T cell infection, but not DC-free T cell infection.  DC-to-T cell 
transmission of HIV may have important implications for viral persistence in vivo.        
  
INTRODUCTION 
Cell-to-cell transmission of HIV is a robust mode of infection, whereby multiple virions 
infect a target cell (Sigal et al., 2011). During this process, a synapse forms between the 
infected donor and uninfected target CD4+ T cells(Sattentau, 2011, Jolly et al., 2011, 
Sattentau, 2008, McDonald et al., 2003).  This close physical proximity enables a high 
number of virions to be transmitted from the infected donor cell to the uninfected target 
cell, resulting in a reduced sensitivity to anti-retroviral drugs (Sigal et al., 2011, Sigal and 
Baltimore, 2012).   Cell-to-cell transmission of HIV via a synapse can also occur 
between DCs and CD4+ T cells (McDonald et al., 2003, Felts et al., 2010).  Infection of 
the donor DC is not required because DCs can capture infectious virions and transmit 
them to uninfected target T cells via trans infection (Wu and KewalRamani, 2006, 
Cameron et al., 1992, Dong et al., 2007).  It is unclear if DC-to-T cell transmission of HIV 
is a robust and drug-insensitive mode of infection. 
 
In this study we found that human monocyte-derived DCs amplify HIV infection of 
autologous T cells in co-culture.  This mode of transmission is relatively resistant to 
reverse transcriptase inhibitors compared to T cell infection in the absence of DCs.  
Further, it is dependent on physical contact between DCs and T cells.  The drug 
insensitivity of DC-to-T cell infection is dependent on the virus input. 
 
RESULTS 
DCs amplify T cell infection 
To determine the effect of DCs on HIV infection of T cells, we infected PBMCs with NL4-
3 in the presence or absence of autologous human monocyte-derived DCs. DCs were 
matured with LPS prior to co-culture with T cells (Supplementary Fig. 1).  Previous 
work indicates that LPS-matured DCs capture significantly more HIV-1 than immature 
DCs (Dong et al., 2007, Izquierdo-Useros et al., 2014).  To measure T cell infection, 
cells were analyzed for CD3 surface expression and intracellular p24 by flow cytometry.  
We found that T cell infection was on average 4-fold higher in DC-T cell coculture 
compared to DC-free culture across multiple donors (Fig. 1, Supplementary Fig. 2).  As 
previously described, LPS-matured DCs showed little evidence of infection by p24 
staining (Granelli-Piperno et al., 1999).  The ability of DCs to amplify HIV infection was 
not specific to the viral strain.  We observed that DC amplification of T cell infection 
occurred with various CXCR4-tropic, CCR5-tropic, dual-tropic, and transmitted founder 
strains (Supplementary Fig. 3).   
 
DC-T cell transmission of HIV is drug-resistant 
We next asked whether DC amplification of T cell infection leads to anti-retroviral drug 
insensitivity. We compared T cell infection in DC-free culture and DC-T cell coculture in 
the presence or absence of the reverse transcriptase inhibitor Tenofovir.  We found that 
T cell infection decreased precipitously in the DC-free culture compared to DC-T cell 
coculture (Fig. 2a).  We previously quantified T cell infection sensitivity to drugs using 
the transmission index (TX), which is the fraction of T cells infected in the presence of 
drug divided by the fraction of T cells infected in the absence of drug (Sigal et al., 2011).  
Drug insensitivity (TX) is dependent on the number of infectious particles transmitted to 
the target T cells. Thus, if the multiplicity of infection (m.o.i) of the target T cell is low, 
then infection is sensitive to the effect of drugs and TX will be <<1. Alternatively, if the 
m.o.i. is high, then infection is insensitive to the effect of drugs and TX will approach 1.  
We found the TX in DC-T coculture was 4-fold higher compared to DC-free culture (Fig. 
2b), suggesting that the ability of DCs to concentrate and transmit a high number of 
virions to a target T cells results in a relatively drug-insensitive mode of infection. 
 
DC-T cell transmission requires cell-to-cell contact 
We next determined if amplification of T cell infection and drug insensitivity was 
dependent on cell-to-cell contact between DCs and T cells. We found amplification (Fig. 
3a) and drug insensitivity (Fig. 3a,b) of T cell infection were abolished if DCs and T cells 
were physically separated by a transwell membrane.  These data suggest drug-
insensitivity associated with DC-to-T cell infection is due to the DC’s ability to 
concentrate and transmit virions to T cell through physical interactions.   
  
Virus input is important to DC-T cell transmission 
We next sought to determine the effect of virus input on drug insensitivity.  Despite 
increasing the amount of NL4-3 added to DC-free culture, TX was unaffected (Fig. 4).  
However, as the virus input was increased in DC-T cell cocultures, the TX also increased, 
indicating DC-to-T cell transmission is dependent on the amount of virus in the system.   
These results suggest that the drug insensitivity of DC-to-T cell transmission is directly 
related to the amount of virions available for capture and transmission by DCs.  
 
DISCUSSION 
In our previous work we found that cell-to-cell transmission between an infected donor T 
cell and an uninfected T cell target was a high multiplicity of infection, which allowed for 
ongoing replication in the presence of anti-retroviral drug (Sigal et al., 2011).  Others 
have also found cell-to-cell transmission to be dependent on high local concentrations of 
virus particles at sites of cellular contacts (Monel et al., 2012).  In this report, we 
examined cell-to-cell transmission of HIV between DCs and T cells and asked whether 
this mode of transmission would allow replication in the presence of anti-retroviral drug.  
We found that DCs were essential to two processes.  First, consistent with previous work, 
we found DCs were difficult to infect and their infection was not required for robust 
amplification of T cell infection (Granelli-Piperno et al., 1999).   This DC-mediated 
enhancement of T cell infection was entirely dependent on cell-to-cell contact.  Second, 
DC-to-T cell infection displayed reduced sensitivity to anti-retroviral drug and also 
required physical contact between the donor DCs and target T cells.  We further found 
that drug insensitivity of DC-to-T cell transmission increased as the virus input was 
increased.  In contrast, the amount of virus in the system had no effect on drug 
insensitivity of DC-free T cell infection.  These results suggest that DCs can efficiently 
capture virions and direct them to T cell targets, which leads to amplification of T cell 
infection and anti-retroviral drug insensitivity. Without DCs, primary T cell infection is a 
very inefficient process. 
 
Our findings raise important questions regarding the importance of DCs in the cell-to-cell 
spread of HIV.  During initial infection, DCs are among the first immune cells to 
encounter HIV at mucosal surfaces (Wu and KewalRamani, 2006).  It is possible that 
DCs carry virions back to lymphoid organs where DC-to-T cell transmission plays an 
important mode of spreading the virus.  The contribution of DCs to the viral reservoir is 
under investigation.  Others have found follicular DCs capture infectious virus for days 
and transmit them to T cells, suggesting a possible cellular virus reservoir (Keele et al., 
2008).   
 
We suspect the mode of viral transmission may also be an important factor contributing 
to the viral reservoir.  The high multiplicity of infection associated with cell-to-cell 
infection allows for anti-retroviral drug insensitivity, which leads to active replication 
(Sigal et al., 2011).  This may be especially problematic in certain anatomical niches 
such as lymphoid tissue, which are conducive to cell-to-cell interactions and have been 
found to also have reduced anti-retroviral drug level (Fletcher et al., 2014).  Thus, DC-to-
T cell transmission may have real implications for persistent virus replication and 
reservoir replenishment in vivo.  It is interesting to speculate whether cell-to-cell 
transmission of HIV contributes to low-level viremia in HIV-infected patients on anti-
retroviral therapy.  Altogether, if the viral reservoir is to be eradicated, then a deeper 
understanding of factors contributing to its formation and maintenance is required. 
 
EXPERIMENTAL PROCEDURES 
Antibodies and Flow cytometry. Single-cell suspensions were stained with the 
following antibodies from Biolegend: PE-anti-human CD11c (301606), PerCP-anti-
human CD14 (325621), APC-anti-human CD86 (305411), and APC/Cy7-anti-human 
HLA-DR (307617). For dead cell staining, 1ug ml-1 of propidium iodine was added. Cells 
were analyzed on a MACSQuant analyzer (Miltenyi), and data were analyzed with 
FlowJo software (TreeStar). 
 
Generation of DCs. Human moDCs were generated by culture for 7 d of CD14+ 
peripheral blood monocytes (UCLA Center for AIDS Research (CFAR) Virology Core 
Lab) in media containing human GM-CSF and IL-4 (Peprotech). DCs were cultured in 
RPMI-1640 medium supplemented with 10% (vol/vol) fetal bovine serum (FBS) (Sigma), 
1% (vol/vol) non-essential amino acids (HyClone), 1mM sodium pyruvate (Gibco), 10mM 
HEPES (Gibco), and 0.05mM 2-mercaptoethanol (Gibco).   
 
Virus Production. The pNL4-3 plasmid used to generate infectious HIV-1 was obtained 
from the AIDS Reagent Program, Division of AIDS, NIAID, NIH.  Virus was prepared by 
culturing HEK293T/17 cells in 10-cm tissue culture dishes and transfecting with BioT 
(Bioland Scientific, Paramount CA) according to manufacturer's instructions using a total 
of 10 µg DNA pMDLg/pRRE and pRSV-Rev. All viral supernatants were harvested at 36, 
48, and 60 h post-transfection and filtered through a 0.45-µm filter. The concentration of 
gag was measured by p24 capture ELISA Kit (ImmunoDiagnostics). 
 
Statistical Analyses. GraphPad Prism 6.0 software was used for data analysis.  
Statistical significance was determined by unpaired, two-sided Student’s t-tests for two 
groups or one-way ANOVA (with post-hoc Tukeys’ multiple comparison test) for three or 
more groups.  
  
FIGURE LEGENDS 
Figure 1. DCs significantly amplify T cell infection. (a) Infection of PBMCs with 
(center) or without DCs (left) in co-culture was analyzed by flow cytometry.  Uninfected 
DC-T coculture (right) was included as a negative control.  Number in the top right gate 
indicates percentage of infected T cells.  (b) Percentages of p24+ T cells were measured 
in infected DC-free culture or DC-T cell co-culture.  Each symbol represents one donor. 
Mean ± s.e.m (η = 6 donors). Data is representative of six independent experiments (a) 
or pooled from six independent experiments (b). 
 
Figure 2. DC-T cell infection is drug-resistant. (a) Infection of DC-free PBMCs (left 
two plots) or DC-T cell co-culture (right two plots) in the absence of presence of 10µm of 
TFV.  (b) Transmission index when infection occurs in DC-free culture (blue bars or 
squares) or DC-T cell coculture.  TFV at 0 µM, 5 µM, 10 µM (wedges). Mean ± s.e.m (η 
= 3 donors). Data is from one experiment (a,b). 
 
Figure 3. DC-T cell drug resistance depends on physical contact between cells. (a) 
Infection of DC-free PBMCs or DC-T cell co-culture with (bottom) or without (top) a 
transwell system, in which DCs are physically separated from PBMCs by a transwell 
membrane.  Infection occurs in the absence of presence of 10µm of TFV.  (b) 
Transmission index when infection occurs in DC-free culture or DC-T cell coculture with 
or without 10 µM of TFV in the absence of presence of a transwell system. Mean ± s.e.m 
(η = 3 donors). Data is from one experiment (a,b). 
 
Figure 4. DC-to-T cell transmission is dependent on the amount of virus in the 
system.  DC-free culture (left) or DC-T cell co-culture (right) were infected with varying 
amounts of NL4-3 in the absence of presence of 10µm of TFV.  x-axis is ng of p24 of 
NL4-3.  y-axis is the transmission index. Each symbol represents a donor.  Data is 
representative of one experiment. 
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SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Figure 1. LPS activation of monocyte-derived DCs.  DCs were 
treated with LPS and analyzed by flow cyotometry. (a) Number in the top left gate 
indicates percentage of cells with the DC phenotype CD14-DC-SIGN+.  (b) The surface 
expression of activation markers CD86 and HLA-DR were analyzed.  Data is 
representative of two independent experiments. 
 
Supplementary Figure 2. DC amplification of HIV infection of T cells in six donors.  
Infection of PBMCs in the presence or absence of DCs was analyzed by flow cytometry. 
Percentages of infected p24+ T cells were measured in six donors.  Each symbol 
represents a technical replicate. Horizontal bar indicates the mean.  Data is 
representative of six independent experiments. 
 
Supplementary Figure 3. DC amplification of T cell infection with different HIV-1 
strains.  Infection of PBMCs with or without DCs by CXCR4-tropic (LAI), CCR5 tropic 
(JRCSF, NFNSX), dual-tropic (89.6) and CCR5-tropic founder strains (11745, 11739) 
were analyzed by flow cytometry. Number in the top right gate indicates percentage of 
infected T cells.   
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 Chapter 4: Conclusions and Future Directions 
 
 
 
 
 
 
CONCLUSIONS 
In this thesis I have uncovered that antigenic protein can be delivered by viral particles via 
pseudotransduction.  This mechanism of protein delivery is sufficient to generate antigen-specific 
immune responses in a mouse model.  Further, I have found that human DNA is a component of 
viral particles and acts as a viral ligand to stimulate the host innate immune STING-dependent 
pathway.  The overall significance, innovation, and future directions of these findings are explored 
in this chapter. 
 
SIGNIFICANCE 
Importance of developing novel vaccine approaches. Over the past two centuries, vaccines 
have led to some of the most important public health achievements including the worldwide 
eradication of smallpox and near-elimination of polio (Henderson, 2011). In addition to protecting 
against pathogens, some of the current vaccines can also prevent against certain types of 
cancers of the liver and cervix (Ungaro et al., 2013).  However, there are many pathogens such 
as HIV, malaria, and tuberculosis, as well as cancers, for which the development of effective 
vaccines has been difficult.  This difficulty is partly due to the fact that intracellular pathogens and 
cancers require robust antigen-specific CD8+ T cell for protection (Wong and Pamer, 2003). A 
protein subunit vaccine, which involves the direct administration of a specific protein from a 
pathogen, is poor at generating CD8+ T cells (Chackerian, 2007). The viral-like particle (VLP) is a 
type of subunit vaccine, which is much more effective at eliciting cell-mediated immune 
responses than other subunit vaccines. They are constructed from few viral proteins and lack a 
viral genome. Despite their simplified nature, VLPs infect cells in a highly immunostimulatory 
fashion, thereby generating antigen-specific CD8+ T responses to their viral proteins. In addition, 
VLPs are a safer alternative than live-attenuated vaccines composed of modified forms of entire 
microbes with reduced pathogenicity, which can be lethal to immunocompromised patients and 
potentially revert to virulent strains. As a consequence, there is a significant need for the 
development of alternative vaccines to target pathogens for which natural protection is inefficient.  
 
Importance of developing future virus-like particle (VLP) vaccines. One important future line 
of research involves the development of recombinant VLPs which capitalize on the immunogenic 
nature of VLPs to deliver the antigens of heterologous pathogens. This type of format could 
greatly simplify future vaccine design and production. In particular, current vaccine manufacturing 
is complex, involving diverse culture systems ranging from mammalian cell lines to insect cell 
lines, and sometimes employing yeast, plant cells, or fertilized chicken eggs (Lua et al., 2014). 
Significant resources are expended in the development, validation, and elucidation of the 
mechanism for each type of VLP. Thus, it is important to explore and develop strategies in which 
a single culture system can generate a broad armament of vaccines against different intracellular 
pathogens and cancers. 
 
Critical barrier to the use of VLPs as vaccines. Understanding the mechanism by which VLPs 
exert their immunostimulatory effect has been a barrier to their use.  These genome-less vectors 
do not contains nucleic acids, which are generally thought to be important in stimulating innate 
immune sensors (Akira et al., 2006, Breckpot et al., 2007, Luban, 2012).  Nevertheless, genome-
less VLPs do trigger innate responses, presumably through interactions of their viral proteins.  
The identification of the immunostimulatory VLP proteins and their corresponding innate immune 
sensing pathways might provide important mechanistic insights with the potential to influence 
future VLP or adjuvant designs.  
 
Potential to understand mechanisms of vaccination and create improved vaccination 
platforms. If the proposed aims are achieved, we will have created a highly flexible and 
simplified method of producing recombinant VLPs with enhanced efficacy. Furthermore, we will 
also have gained an understanding of the mechanisms by which VLPs exert their 
immunostimulatory effect and quantified host immune responses. Collectively, successful 
completion of this proposal could be fundamentally important to future vaccine development by 
expanding our knowledge of viral mechanisms and host responses to infection. 
 
INNOVATION 
The current work is innovative in the following ways.  First, we have discovered an immune 
mechanism used by LVs and VLPs which has identified a previously unknown innate immune 
sensing pathway.  We have found that viral particles encapsulate human DNA, which serves to 
stimulate the host STING pathway.  Secondly, this work explores the use of a dendritic cell (DC)-
targeting VLPs, which have not been previously described.  The DC-targeting Sindbis virus-
derived envelope has been used to specifically direct viral vectors to DCs, which are among the 
most important antigen-presenting cell of the immune system (Yang et al., 2008, Xiao et al., 2012, 
Dai et al., 2009). In this work we have developed a highly efficient DC-targeting VLP. Thirdly, we 
have improved upon the production methods for producing recombinant VLPs delivering 
heterologous antigens from human cell lines.  Currently, recombinant VLPs are made by fusing 
heterologous antigens to the viral proteins of the VLP (Roose et al., 2013, Stoute et al., 1997, 
Neirynck et al., 1999, Vietheer et al., 2007, Arora et al., 2013, Kaczmarczyk et al., 2011, Gheysen 
et al., 1989).  However, the immunodominant epitope may not be known or more than one may 
be required for protection.  Furthermore, fusion of epitopes to viral proteins may disrupt the ability 
of VLPs to self-assemble into particles.  In this thesis we provide an innovative and simple 
method for incorporating whole heterologous proteins into VLPs.  Lastly, this work has generated 
easy ways to produce immunostimulatory vectors and investigate new fundamentally important 
mechanisms of immunity.  
 
FUTURE DIRECTIONS 
These interesting findings lead to further questions about pseudotransduction and human DNA-
mediated immune stimulation. 
1) How does heterologous protein and human DNA get encapsulated into viral particles?  Is 
the mechanism of encapsulation passive or directed? 
2) What is the characterization of human nucleic acids in the viral particles?  What is the 
genetic landscape of dsDNA represented in these viral particles?  Is the whole human 
genome represented randomly or non-randomly? Are there ssDNA as well, which may be 
important to immune stimulation?  Are there human RNA molecules which may also have 
an immunostimulatory function?  Is this process of protein and DNA encapsulation 
generalizable to other viruses and cell types?  Our results suggest this process is not 
specific to the transfection process or 293T cells. Does the viral envelope of HIV also 
induce DC activation similarily to the viral envelope from VSV and Sindbis virus?  
3) Viral particles are known to represent a heterogeneous population of particles.  Do the 
particles differ by heterologous protein and human DNA composition?  Are there methods 
to separate particles based on these components? 
4) What is the innate immune sensor that detects human DNA released via viral fusion into 
the cytoplasm?  Various cytosolic DNA sensors signal through the STING-dependent 
pathway.  It is unclear which of the putative DNA cytosolic sensors are involved in LV 
detection.  In particular, is the dsDNA cytosolic sensor cGAS involved in LV or VLP-
mediated DC stimulation? 
5) It appears that viral fusion itself also stimulates DCs in a STING-independent method.  
What is the mechanism of this STING-independent process? 
6) What role does cell death play in LV-mediated immune stimulation?  Do LV-treated cells 
die by apoptosis?  If so, is autophagy involved? 
7) Can DC-targeting VLPs be used as an effective vaccine?  Can these VLPs protect 
against infectious challenges of intracellular pathogens such as Listeria or LCMV, which 
required potent memory CD8+ T cell responses? 
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